Document:

<PAGE>
                                                                    Exhibit 10.3

                               CLINICAL DATA, INC.
                 AMENDED AND RESTATED 2005 EQUITY INCENTIVE PLAN

                                   ARTICLE 1.
                       BACKGROUND AND PURPOSE OF THE PLAN

      1.1. Background. This Amended and Restated 2005 Equity Incentive Plan (the
"Plan") permits the grant of Incentive Stock Options, Nonstatutory Stock
Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units,
and other equity-based awards.

      1.2. Purpose. The purposes of the Plan are (a) to attract and retain
highly competent persons as Employees, Directors, and Consultants of the
Company; (b) to provide additional incentives to such Employees, Directors, and
Consultants; and (c) to promote the success of the business of the Company.

      1.3. 2002 Plan. The Clinical Data, Inc. 2002 Incentive and Stock Plan (the
"Prior Plan") shall remain in effect in accordance with its terms, and further
option grants may be made under the Prior Plan after the Effective Date. The
adoption of this Plan as of the Effective Date shall not affect the Prior Plan
or the terms of any option granted under the Prior Plan either before or after
the Effective Date.

      1.4. Eligibility. Service Providers who are Employees, Consultants
determined by the Committee to be significantly responsible for the success and
future growth and profitability of the Company, or Directors are eligible to be
granted Awards under the Plan. However, Incentive Stock Options may be granted
only to Employees.

      1.5. Definitions. Capitalized terms used in the Plan and not otherwise
defined herein shall have the meanings assigned to such terms in the attached
Appendix.

                                   ARTICLE 2.
                                  SHARE LIMITS

      2.1. Shares Subject to the Plan.

            (a) Share Reserve. Subject to adjustment under Section 2.3 of the
Plan, two million (2,000,000) Shares shall be initially reserved for issuance
pursuant to Awards made under the Plan. All of the available Shares may, but
need not, be issued pursuant to the exercise of Incentive Stock Options. At all
times the Company will reserve and keep available a sufficient number of Shares
to satisfy the requirements of all outstanding Awards made under the Plan and
all other outstanding but unvested Awards made under the Plan that are to be
settled in Shares.

            (b) Shares Counted Against Limitation. If an Award is exercised, in
whole or in part, by delivery or attestation of Shares under Section 5.4(b), or
if the tax withholding obligation is satisfied by withholding Shares under
Section 10.7(b), the number of Shares deemed to have been issued under the Plan
(for purposes of the limitation set forth in this Section

<PAGE>

2.1) shall be the number of Shares that were subject to the Award or portion
thereof so exercised and not the net number of Shares actually issued upon such
exercise.

            (c) Lapsed Awards. If an Award: (i) expires; (ii) is terminated,
surrendered, or canceled without having been exercised in full; or (iii) is
otherwise forfeited in whole or in part, then the unissued Shares that were
subject to such Award and/or such surrendered, canceled, or forfeited Shares (as
the case may be) shall become available for future grant or sale under the Plan
(unless the Plan has terminated), subject however, in the case of Incentive
Stock Options, to any limitations under the Code.

            (d) Limitation on Full-Value Awards. Not more than five hundred
thousand (500,000) of the total number of Shares reserved for issuance under the
Plan (as adjusted under Section 2.3) may be granted or sold as Awards of
Restricted Stock, Restricted Stock Units, unrestricted grants of Shares, and
other Awards ("full-value Awards") whose intrinsic value is not solely dependent
on appreciation in the price of Shares after the date of grant. Options and
Stock Appreciation Rights shall not be subject to, and shall not count against,
the limit described in the preceding sentence. If a full-value Award expires, is
forfeited, or otherwise lapses as described in Section 2.1(c), the Shares that
were subject to the Award shall be restored to the total number of Shares
available for grant or sale as full-value Awards.

            (e) Substitute Awards. The Committee may grant Awards under the Plan
in substitution for stock and stock based awards held by employees, directors,
consultants or advisors of another company (an "Acquired Company") in connection
with a merger, consolidation or advisors of such Acquired Company with the
Company or an Affiliate or the acquisition by the Company or an Affiliate of
property or stock of the Acquired Company. The Committee may direct that the
substitute Awards be granted on such terms and conditions as the Committee
considers appropriate in the circumstances. Any substitute Awards granted under
the Plan shall not count against the share limitations set forth in Section
2.1(a) and 2.2.

      2.2. Individual Share Limit. In any Tax Year, no Service Provider shall be
granted Awards with respect to more than five hundred thousand (500,000) Shares.
The limit described in this Section 2.2 shall be construed and applied
consistently with Section 162(m) of the Code, except that the limit shall apply
to all Service Providers.

            (a) Awards not Settled in Shares. If an Award is to be settled in
cash or any medium other than Shares, the number of Shares on which the Award is
based shall count toward the individual share limit set forth in this Section
2.2.

            (b) Canceled Awards. Any Awards granted to a Participant that are
canceled shall continue to count toward the individual share limit applicable to
that Participant set forth in this Section 2.2.

      2.3. Adjustments.

            (a) In the event that there is any dividend or distribution payable
in Shares, or any stock split, reverse stock split, combination or
reclassification of Shares, or any other similar change in the number of
outstanding Shares, then the maximum aggregate number of Shares available for
Awards under Section 2.1 of the Plan, the maximum number of Shares issuable to a
Service Provider under Section 2.2 of the Plan, and any other limitation under
this Plan on the maximum number of Shares issuable to an individual or in the
aggregate shall be proportionately

                                      -2-
<PAGE>

adjusted (and rounded down to a whole number) by the Committee as it deems
equitable in its discretion to prevent dilution or enlargement of the rights of
the Participants. The Committee's determination with respect to any such
adjustments shall be conclusive.

            (b) In the event that there is any extraordinary dividend or other
distribution in respect of the Shares, recapitalization, reclassification,
merger, reorganization, consolidation, combination, sale of assets, split-up,
exchange, spin-off or other extraordinary event, then the Committee shall make
provision for a cash payment, for the substitution or exchange of any or all
outstanding Awards or a combination of the foregoing, based upon the
distribution or consideration payable to holders of the Shares in respect of
such event or on such other terms as the Committee otherwise deems appropriate.

                                   ARTICLE 3.
                           ADMINISTRATION OF THE PLAN

      3.1. Administrator. The Plan shall be administered by the Committee.

      3.2. Powers of the Committee. Subject to the provisions of the Plan,
Applicable Law, and the specific duties delegated by the Board to the Committee,
the Committee shall have the authority in its discretion: (a) to determine the
Fair Market Value; (b) to select the Service Providers to whom Awards may be
granted hereunder and the types of Awards to be granted to each; (c) to
determine the number of Shares to be covered by each Award granted hereunder;
(d) to determine whether, to what extent, and under what circumstances an Award
may be settled in cash, Shares, other securities, other Awards, or other
property; (e) to approve forms of Award Agreements; (f) to determine, in a
manner consistent with the terms of the Plan, the terms and conditions of any
Award granted hereunder, based on such factors as the Committee, in its sole
discretion, shall determine; (g) to construe and interpret the terms of the Plan
and Award Agreements; (h) to correct any defect, supply any omission, or
reconcile any inconsistency in the Plan or any Award Agreement in the manner and
to the extent it shall deem desirable to carry out the purposes of the Plan; (i)
to prescribe, amend, and rescind rules and regulations relating to the Plan,
including rules and regulations relating to sub-plans established pursuant to
Section 12.1 of the Plan; (j) to authorize withholding arrangements pursuant to
Section 10.7(b) of the Plan; (k) to authorize any person to execute on behalf of
the Company any instrument required to effect the grant of an Award previously
granted by the Committee; and (l) to make all other determinations and take all
other action described in the Plan or as the Committee otherwise deems necessary
or advisable for administering the Plan and effectuating its purposes.

      3.3. Compliance with Applicable Law. The Committee shall administer,
construe, interpret, and exercise discretion under the Plan and each Award
Agreement in a manner that is consistent and in compliance with a reasonable,
good faith interpretation of all Applicable Laws, and that avoids (to the extent
practicable) the classification of any Award as "deferred compensation" for
purposes of Section 409A of the Code, as determined by the Committee.

      3.4. Effect of Committee's Decision and Committee's Liability. The
Committee's decisions, determinations and interpretations shall be final and
binding on all Participants and any other holders of Awards. Neither the
Committee nor any of its members shall be liable for

                                      -3-
<PAGE>

any act, omission, interpretation, construction, or determination made in good
faith in connection with the Plan or any Award Agreement.

      3.5. Delegation to Executive Officers. To the extent permitted by
Applicable Law, the Board may delegate to one or more Executive Officers the
powers: (a) to designate Service Providers who are not Executive Officers as
eligible to participate in the Plan; and (b) to determine the amount and type of
Awards that may be granted to Service Providers who are not Executive Officers.

      3.6. Awards may be Granted Separately or Together. In the Committee's
discretion, Awards may be granted alone, in addition to, or in tandem with any
other Award or any award granted under another plan of the Company or an
Affiliate. Awards granted in addition to or in tandem with other awards may be
granted either at the same time or at different times.

                                   ARTICLE 4.
                       VESTING AND PERFORMANCE OBJECTIVES

      4.1. General. The vesting schedule or Period of Restriction for any Award
shall be specified in the Award Agreement. The criteria for vesting and for
removing restrictions on any Award may include (i) performance of substantial
services for the Company for a specified period; (ii) achievement of one or more
Performance Objectives; or (iii) a combination of (i) and (ii), as determined by
the Committee.

      4.2. Period of Absence from Providing Substantial Services. To the extent
that vesting or removal of restrictions is contingent on performance of
substantial services for a specified period, a leave of absence (whether paid or
unpaid) shall not count toward the required period of service unless the Award
Agreement provides otherwise.

      4.3. Performance Objectives.

            (a) Possible Performance Objectives. Any Performance Objective shall
relate to the Service Provider's performance for the Company (or an Affiliate)
or the Company's (or Affiliate's) business activities or organizational goals,
and shall be sufficiently specific that a third party having knowledge of the
relevant facts could determine whether the Performance Objective is achieved.
The Performance Objectives with respect to any Award may be one or more of the
following General Financial and/or Operational Objectives, as established by the
Committee in its sole discretion:

                  (i) General Financial Objectives:

  -   Increasing the Company's net sales

  -   Achieving a target level of earnings (including gross earnings; earnings
      before certain deductions, such as interest, taxes, depreciation, or
      amortization; or earnings per Share)

  -   Achieving a target level of income (including net income or income before
      consideration of certain factors, such as overhead) or a target level of
      gross profits for the Company, an Affiliate, or a business unit

  -   Achieving a target return on the Company's (or an Affiliate's) capital,
      assets, or stockholders' equity

                                      -4-
<PAGE>

  -   Maintaining or achieving a target level of appreciation in the price of
      the Shares

  -   Increasing the Company's (or an Affiliate's) market share to a specified
      target level

  -   Achieving or maintaining a Share price that meets or exceeds the
      performance of specified stock market indices or other benchmarks over a
      specified period

  -   Achieving a level of Share price, earnings, or income performance that
      meets or exceeds performance in comparable areas of peer companies over a
      specified period

  -   Achieving specified reductions in costs

  -   Achieving specified improvements in collection of outstanding accounts or
      specified reductions in non-performing debts

                  (ii) Operational Objectives:

  -   Expanding one or more products into one or more new markets

  -   Acquiring a prescribed number of new customers in a line of business

  -   Achieving a prescribed level of productivity within a business unit

  -   Completing specified projects within or below the applicable budget

            (b) Stockholder Approval of Performance Objectives. The list of
possible Performance Objectives set forth in Section 4.3(a), above, and the
other material terms of Awards of Restricted Stock or Restricted Stock Units
that are intended to qualify as "performance-based compensation" under Section
162(m) of the Code, shall be subject to reapproval by the Company's stockholders
at the first stockholder meeting that occurs in 2010. No Award of Restricted
Stock or Restricted Stock Units that is intended to qualify as
"performance-based compensation" under Section 162(m) of the Code shall be made
after that meeting unless stockholders have reapproved the list of Performance
Objectives and other material terms of such Awards, or unless the vesting of the
Award is made contingent on stockholder approval of the Performance Objectives
and other material terms of such Awards.

            (c) Documentation of Performance Objectives. With respect to any
Award, the Performance Objectives shall be set forth in writing no later than 90
days after commencement of the period to which the Performance Objective(s)
relate(s) (or, if sooner, before 25% of such period has elapsed) and at a time
when achievement of the Performance Objectives is substantially uncertain. Such
writing shall also include the period for measuring achievement of the
Performance Objectives, which shall be no greater than five consecutive years,
as established by the Committee. Once established by the Committee, the
Performance Objective(s) may not be changed to accelerate the settlement of an
Award or to accelerate the lapse or removal of restrictions on Restricted Stock
that otherwise would be due upon the attainment of the Performance Objective(s).

            (d) Committee Certification. Prior to settlement of any Award that
is contingent on achievement of one or more Performance Objectives, the
Committee shall certify in writing that the applicable Performance Objective(s)
and any other material terms of the Award were in fact satisfied. For purposes
of this Section 4.3(d), approved minutes of the Committee shall be adequate
written certification.

                                      -5-
<PAGE>

            (e) Negative Discretion. The Committee may reduce, but may not
increase, the number of Shares deliverable or the amount payable under any Award
after the applicable Performance Objectives are satisfied.

                                   ARTICLE 5.
                                  STOCK OPTIONS

      5.1. Terms of Option. Subject to the provisions of the Plan, the type of
Option, term, exercise price, vesting schedule, and other conditions and
limitations applicable to each Option shall be as determined by the Committee
and shall be stated in the Award Agreement.

      5.2. Type of Option.

            (a) Each Option shall be designated in the Award Agreement as either
an Incentive Stock Option or a Nonstatutory Stock Option.

            (b) Neither the Company nor the Committee shall have liability to a
Participant or any other party if an Option (or any part thereof) which is
intended to be an Incentive Stock Option does not qualify as an Incentive Stock
Option. In addition, the Committee may make an adjustment or substitution
described in Section 2.3 of the Plan that causes the Option to cease to qualify
as an Incentive Stock Option without the consent of the affected Participant or
any other party.

      5.3. Limitations.

            (a) Maximum Term. No Option shall have a term in excess of 10 years
measured from the date the Option is granted. In the case of any Incentive Stock
Option granted to a 10% Stockholder (as defined in Section 5.3(e), below), the
term of such Incentive Stock Option shall not exceed five years measured from
the date the Option is granted.

            (b) Minimum Exercise Price. Subject to Section 2.3(b) of the Plan,
the exercise price per share of an Option shall not be less than 100% of the
Fair Market Value per Share on the date the Option is granted. In the case of
any Incentive Stock Option granted to a 10% Stockholder (as defined in Section
5.3(e), below), subject to Section 2.3(b) of the Plan, the exercise price per
share of such Incentive Stock Option shall not be less than 110% of the Fair
Market Value per Share on the date the Option is granted.

            (c) Repricing Prohibited. Except as provided in Section 2.3, the
Committee shall not amend any outstanding Option to reduce its exercise price,
and shall not grant an Option with a lower exercise price within six months
before or after an Option with a higher exercise price is canceled.

            (d) $100,000 Limit for Incentive Stock Options. Notwithstanding an
Option's designation, to the extent that Incentive Stock Options are exercisable
for the first time by the Participant during any calendar year with respect to
Shares whose aggregate Fair Market Value exceeds $100,000 (regardless of whether
such Incentive Stock Options were granted under this Plan, the 2002 Plan, or any
other plan of the Company or any Affiliate), such Options shall be treated as
Nonstatutory Stock Options. For purposes of this Section 5.3(d), Fair Market
Value shall be measured as of the date the Option was granted and Incentive
Stock Options shall be taken into account in the order in which they were
granted.

                                      -6-
<PAGE>

            (e) 10% Stockholder. For purposes of this Section 5.3, a "10%
Stockholder" is an individual who, immediately before the date an Award is
granted, owns (or is treated as owning) stock possessing more than 10% of the
total combined voting power of all classes of stock of the Company (or an
Affiliate), determined under Section 424(d) of the Code.

      5.4. Form of Consideration. The Committee shall determine the acceptable
form of consideration for exercising an Option, including the method of payment.
In the case of an Incentive Stock Option, the Committee shall determine the
acceptable form of consideration at the time of grant. To the extent approved by
the Committee, the consideration for exercise of an Option may be paid in any
one, or any combination, of the forms of consideration set forth in subsections
(a), (b), and (c), below.

            (a) Cash Equivalent. Consideration may be paid by cash, check, or
other cash equivalent approved by the Committee.

            (b) Tender or Attestation of Shares. Consideration may be paid by
the tendering of other Shares to the Company or the attestation to the ownership
of the Shares that otherwise would be tendered to the Company in exchange for
the Company's reducing the number of Shares issuable upon the exercise of the
Option. Shares tendered or attested to in exchange for Shares issued under the
plan must be held by the Service Provider for at least six months prior to their
tender or their attestation to the Company and may not be shares of Restricted
Stock at the time they are tendered or attested to. The Committee shall
determine acceptable methods for tendering or attesting to Shares to exercise an
Option under the Plan and may impose such limitations and prohibitions on the
use of Shares to exercise Options as it deems appropriate. For purposes of
determining the amount of the Option price satisfied by tendering or attesting
to Shares, such Shares shall be valued at their Fair Market Value on the date of
tender or attestation, as applicable.

            (c) Other Methods. Consideration may be paid using such other
methods of payment as the Committee, at its discretion, deems appropriate from
time to time.

      5.5. Exercise of Option.

            (a) Procedure for Exercise. Any Option granted hereunder shall be
exercisable according to the terms of the Plan and at such times and under such
conditions as set forth in the Award Agreement. An Option shall be deemed
exercised when the Committee receives: (i) written or electronic notice of
exercise (in accordance with the Award Agreement) from the person entitled to
exercise the Option and (ii) full payment for the Shares (in a form permitted
under Section 5.4 of the Plan) with respect to which the Option is exercised.

            (b) Termination of Relationship as a Service Provider. Following a
Participant's Termination of Service, the Participant (or the Participant's
Beneficiary, in the case of Termination of Service due to death) may exercise
his or her Option within such period of time as is specified in the Award
Agreement, subject to the following conditions:

                  (i) An Option may be exercised after the Participant's
Termination of Service only to the extent that the Option was vested as of the
Termination of Service;

                  (ii) An Option may not be exercised after the expiration of
the term of such Option as set forth in the Award Agreement;

                                      -7-
<PAGE>

                  (iii) Unless a Participant's Termination of Service is the
result of the Participant's Disability, the Participant may not exercise an
Incentive Stock Option more than three months after such Termination of Service;

                  (iv) If a Participant's Termination of Service is the result
of the Participant's Disability, the Participant may exercise an Incentive Stock
Option up to 12 months after Termination of Service; and

                  (v) After the Participant's death, his Beneficiary may
exercise an Incentive Stock Option only to the extent that that the deceased
Participant was entitled to exercise such Incentive Stock Option as of the date
of his death.

In the absence of a specified time in the Award Agreement, the Option shall
remain exercisable for three months after the Participant's Termination of
Service for any reason other than Disability or death, and for 12 months after
the Participant's Termination of Service on account of Disability or death.

            (c) Rights as a Stockholder. Shares subject to an Option shall be
deemed issued, and the Participant shall be deemed the record holder of such
Shares, on the Option exercise date. Until such Option exercise date, no right
to vote or receive dividends or any other rights as a stockholder shall exist
with respect to the Shares subject to the Option. In the event that the Company
effects a split of the Shares by means of a stock dividend and the exercise
price of, and number of shares subject to, an Option are adjusted as of the date
of distribution of the dividend (rather than as of the record date for such
dividend), then a Participant who exercises such Option between the record date
and the distribution date for such stock dividend shall be entitled to receive,
on the distribution date, the stock dividend with respect to the Shares subject
to the Option. No other adjustment shall be made for a dividend or other right
for which the record date is prior to the date the Shares are issued.

      5.6. Repurchase Rights. The Committee shall have the discretion to grant
Options which are exercisable for unvested Shares. If the Participant ceases to
be a Service Provider while holding such unvested Shares, the Company shall have
the right to repurchase any or all of those unvested Shares at a price per share
equal to the lower of (i) the exercise price paid per Share, or (ii) the Fair
Market Value per Share at the time of repurchase. The terms upon which such
repurchase right shall be exercisable by the Committee (including the period and
procedure for exercise and the appropriate vesting schedule for the purchased
Shares) shall be established by the Committee and set forth in the document
evidencing such repurchase right.

                                   ARTICLE 6.
                            STOCK APPRECIATION RIGHTS

      6.1. Terms of Stock Appreciation Right. The term, base amount, vesting
schedule, and other conditions and limitations applicable to each Stock
Appreciation Right, except the medium of settlement, shall be as determined by
the Committee and shall be stated in the Award Agreement. All Awards of Stock
Appreciation Rights shall be settled in Shares issuable upon the exercise of the
Stock Appreciation Right.

                                      -8-
<PAGE>

      6.2. Exercise of Stock Appreciation Right.

            (a) Procedure for Exercise. Any Stock Appreciation Right granted
hereunder shall be exercisable according to the terms of the Plan and at such
times and under such conditions as set forth in the Award Agreement. A Stock
Appreciation Right shall be deemed exercised when the Committee receives written
or electronic notice of exercise (in accordance with the Award Agreement) from
the person entitled to exercise the Stock Appreciation Right.

            (b) Termination of Relationship as a Service Provider. Following a
Participant's Termination of Service, the Participant (or the Participant's
Beneficiary, in the case of Termination of Service due to death) may exercise
his or her Stock Appreciation Right within such period of time as is specified
in the Award Agreement to the extent that the Stock Appreciation right is vested
as of the Termination of Service. In the absence of a specified time in the
Award Agreement, the Stock Appreciation Right shall remain exercisable for three
months following the Participant's Termination of Service for any reason other
than Disability or death, and for 12 months after the Participant's Termination
of Service on account of Disability or death.

            (c) Rights as a Stockholder. Shares subject to a Stock Appreciation
Right shall be deemed issued, and the Participant shall be deemed the record
holder of such Shares, on the date the Stock Appreciation Right is exercised.
Until such date, no right to vote or receive dividends or any other rights as a
stockholder shall exist with respect to the Shares subject to the Stock
Appreciation Right. If the Company effects a split of the Shares by means of a
stock dividend and the exercise price of, and number of shares subject to, a
Stock Appreciation Right are adjusted as of the date of distribution of the
dividend (rather than as of the record date for such dividend), then a
Participant who exercises such Stock Appreciation Right between the record date
and the distribution date for such stock dividend shall be entitled to receive,
on the distribution date, the stock dividend with respect to the Shares subject
to the Stock Appreciation Right. No other adjustment shall be made for a
dividend or other right for which the record date is prior to the date the
Shares are issued.

                                   ARTICLE 7.
                                RESTRICTED STOCK

      7.1. Terms of Restricted Stock. Subject to the provisions of the Plan, the
Period of Restriction, the number of Shares granted, and other conditions and
limitations applicable to each Award of Restricted Stock shall be as determined
by the Committee and shall be stated in the Award Agreement. Unless the
Committee determines otherwise, Shares of Restricted Stock shall be held by the
Company as escrow agent until the restrictions on such Shares have lapsed.

      7.2. Transferability. Except as provided in this Article 7, Shares of
Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise
alienated or hypothecated until the end of the applicable Period of Restriction.

      7.3. Other Restrictions. The Committee, in its sole discretion, may impose
such other restrictions on Shares of Restricted Stock as it may deem advisable
or appropriate.

                                      -9-
<PAGE>

      7.4. Removal of Restrictions. Except as otherwise provided in this Article
7, and subject to Section 10.5 of the Plan, Shares of Restricted Stock covered
by an Award of Restricted Stock made under the Plan shall be released from
escrow, and shall become fully transferable, as soon as practicable after the
Period of Restriction ends, and in any event no later than 2-1/2 months after
the end of the Tax Year in which the Period of Restriction ends.

      7.5. Voting Rights. During the Period of Restriction, Service Providers
holding Shares of Restricted Stock granted hereunder may exercise full voting
rights with respect to those Shares, unless otherwise provided in the Award
Agreement. 7.6. Dividends and Other Distributions. During the Period of
Restriction, Service Providers holding Shares of Restricted Stock shall be
entitled to receive all dividends and other distributions paid with respect to
such Shares unless otherwise provided in the Award Agreement.

            (a) If any such dividends or distributions are paid in Shares, the
Shares shall be subject to the same restrictions (and shall therefore be
forfeitable to the same extent) as the Shares of Restricted Stock with respect
to which they were paid.

            (b) If any such dividends or distributions are paid in cash, the
Award Agreement may specify that the cash payments shall be subject to the same
restrictions as the related Restricted Stock, in which case they shall be
accumulated during the Period of Restriction and paid or forfeited when the
related Shares of Restricted Stock vest or are forfeited. Alternatively, the
Award Agreement may specify that the dividend equivalents or other payments
shall be unrestricted, in which case they shall be paid as soon as practicable
after the dividend or distribution date. In no event shall any cash dividend or
distribution be paid later than 2-1/2 months after the Tax Year in which the
dividend or distribution becomes nonforfeitable.

      7.7. Right of Repurchase of Restricted Stock. If, with respect to any
Award, (a) a Participant's Termination of Service occurs before the end of the
Period of Restriction or (b) any Performance Objectives are not achieved by the
end of the period for measuring such Performance Objectives, then the Company
shall have the right to repurchase forfeitable Shares of Restricted Stock from
the Participant at their original issuance price or other stated or formula
price (or to require forfeiture of such Shares if issued at no cost).

                                   ARTICLE 8.
                             RESTRICTED STOCK UNITS

      8.1. Terms of Restricted Stock Units. Subject to the provisions of the
Plan, the Period of Restriction, number of underlying Shares, and other
conditions and limitations applicable to each Award of Restricted Stock Units
shall be as determined by the Committee and shall be stated in the Award
Agreement.

      8.2. Settlement of Restricted Stock Units. Subject to Section 10.5 of the
Plan, the number of Shares specified in the Award Agreement, or cash equal to
the Fair Market Value of the underlying Shares specified in the Award Agreement,
shall be delivered to the Participant as soon as practicable after the end of
the applicable Period of Restriction, and in any event no later than 2-1/2
months after the end of the Tax Year in which the Period of Restriction ends.

                                      -10-
<PAGE>

      8.3. Dividend and Other Distribution Equivalents. The Committee is
authorized to grant to holders of Restricted Stock Units the right to receive
payments equivalent to dividends or other distributions with respect to Shares
underlying Awards of Restricted Stock Units. The Award Agreement may specify
that the dividend equivalents or other distributions shall be subject to the
same restrictions as the related Restricted Stock Units, in which case they
shall be accumulated during the Period of Restriction and paid or forfeited when
the related Restricted Stock Units are paid or forfeited. Alternatively, the
Award Agreement may specify that the dividend equivalents or other distributions
shall be unrestricted, in which case they shall be paid on the dividend or
distribution payment date for the underlying Shares, or as soon as practicable
thereafter. In no event shall any unrestricted dividend equivalent or other
distribution be paid later than 2-1/2 months after the Tax Year in which the
record date for the dividend or distribution occurs.

      8.4. Forfeiture. If, with respect to any Award, (a) a Participant's
Termination of Service occurs before the end of the Period of Restriction, or
(b) any Performance Objectives are not achieved by the end of the period for
measuring such Performance Objectives, then the Restricted Stock Units granted
pursuant to such Award shall be forfeited and the Company (and any Affiliate)
shall have no further obligation thereunder.

                                   ARTICLE 9.
                            OTHER EQUITY-BASED AWARDS

      9.1. Other Equity-Based Awards. The Committee shall have the right to
grant other Awards based upon or payable in Shares having such terms and
conditions as the Committee may determine, including the grant of Shares upon
the achievement of a Performance Objective and the grant of securities
convertible into Shares.

                                  ARTICLE 10.
                           ADDITIONAL TERMS OF AWARDS

      10.1. No Rights to Awards. No Service Provider shall have any claim to be
granted any Award under the Plan, and the Company is not obligated to extend
uniform treatment to Participants or Beneficiaries under the Plan. The terms and
conditions of Awards need not be the same with respect to each Participant.

      10.2. No Effect on Employment or Service. Neither the Plan nor any Award
shall confer upon a Participant any right with respect to continuing the
Participant's relationship as a Service Provider with the Company; nor shall
they interfere in any way with the Participant's right or the Company's right to
terminate such relationship at any time, with or without cause, to the extent
permitted by Applicable Laws and any enforceable agreement between the Service
Provider and the Company.

      10.3. No Fractional Shares. No fractional Shares shall be issued or
delivered pursuant to the Plan or any Award, and the Committee shall determine
whether cash, other securities, or other property shall be paid or transferred
in lieu of any fractional Shares, or whether such fractional Shares or any
rights thereto shall be canceled, terminated, or otherwise eliminated.

                                      -11-
<PAGE>

      10.4. Transferability of Awards. Unless otherwise determined by the
Committee, an Award may not be sold, pledged, assigned, hypothecated,
transferred, or disposed of in any manner other than by will or by the laws of
descent or distribution and may be exercised, during the lifetime of the
Participant, only by the Participant. Subject to the approval of the Committee
in its sole discretion, Nonstatutory Stock Options may be transferable to
members of the immediate family of the Participant and to one or more trusts for
the benefit of such family members, partnerships in which such family members
are the only partners, or corporations in which such family members are the only
stockholders. "Members of the immediate family" means the Participant's spouse,
children, stepchildren, grandchildren, parents, grandparents, siblings
(including half brothers and sisters), and individuals who are family members by
adoption. To the extent that any Award is transferable, such Award shall contain
such additional terms and conditions as the Committee deems appropriate.

      10.5. Conditions On Delivery of Shares and Lapsing of Restrictions. The
Company shall not be obligated to deliver any Shares pursuant to the Plan or to
remove restrictions from Shares previously delivered under the Plan until (a)
all conditions of the Award have been met or removed to the satisfaction of the
Committee, (b) subject to approval of the Company's counsel, all other legal
matters (including any Applicable Laws) in connection with the issuance and
delivery of such Shares have been satisfied, and (c) the Participant has
executed and delivered to the Company such representations or agreements as the
Committee may consider appropriate to satisfy the requirements of Applicable
Laws.

      10.6. Inability to Obtain Authority. The inability of the Company to
obtain authority from any regulatory body having jurisdiction, which authority
is deemed by the Company's counsel to be necessary to the lawful issuance and
sale of any Shares hereunder, shall relieve the Company of any liability in
respect of the failure to issue or sell such Shares as to which such requisite
authority shall not have been obtained.

      10.7. Withholding.

            (a) Withholding Requirements. Prior to the delivery of any Shares or
cash pursuant to the grant, exercise, vesting, or settlement of an Award, the
Company shall have the power and the right to deduct or withhold, or to require
a Participant or Beneficiary to remit to the Company, an amount sufficient to
satisfy any federal, state, and local taxes (including the Participant's FICA
obligation) that the Company determines is required to be withheld to comply
with Applicable Laws. The Participant or Beneficiary shall remain responsible at
all times for paying any federal, state, and local income or employment tax due
with respect to any Award, and the Company shall not be liable for any interest
or penalty that a Participant or Beneficiary incurs by failing to make timely
payments of tax.

            (b) Withholding Arrangements. The Committee, in its sole discretion
and pursuant to such procedures as it may specify from time to time, may permit
a Participant or Beneficiary to satisfy such tax withholding obligation, in
whole or in part, by (i) electing to have the Company withhold otherwise
deliverable Shares, or (ii) delivering to the Company already-owned Shares
having a Fair Market Value equal to the amount required by Applicable Law to be
withheld. The Fair Market Value of the Shares to be withheld or delivered, or
with respect to which restrictions are removed, shall be determined as of the
date that the taxes are required to be withheld.

                                      -12-
<PAGE>

      10.8. Other Provisions in Award Agreements. In addition to the provisions
described in the Plan, any Award Agreement may include such other provisions
(whether or not applicable to the Award of any other Participant) as the
Committee determines appropriate, including restrictions on resale or other
disposition, provisions for the acceleration of exercisability of Options and
Stock Appreciation Rights in the event of a change in control of the Company,
provisions for the cancellation of Awards in the event of a change in control of
the Company, and provisions to comply with Applicable Laws.

      10.9. Section 16 of the Exchange Act. It is the intent of the Company that
Awards and transactions permitted by Awards be interpreted in a manner that, in
the case of Participants who are or may be subject to Section 16 of the Exchange
Act, qualify, to the maximum extent compatible with the express terms of the
Awards, for exemption from matching liability under Rule 16b-3 promulgated under
the Exchange Act. The Company shall have no liability to any Participant or
other person for Section 16 consequences of Awards or events in connection with
Awards if an Award or related event does not so qualify.

      10.10. Not Benefit Plan Compensation. Payments and other benefits received
by a Participant under an Award made pursuant to the Plan shall not be deemed a
part of a Participant's compensation for purposes of determining the
Participant's benefits under any other employee benefit plans or arrangements
provided by the Company or an Affiliate, except where the Committee expressly
provides otherwise in writing.

                                  ARTICLE 11.
                    TERM, AMENDMENT, AND TERMINATION OF PLAN

      11.1. Term of Plan. The Plan shall become effective on the Effective Date.

      11.2. Termination of the Plan. The Plan shall terminate upon the earliest
to occur of (i) July 27, 2015; (ii) the date that is 10 years after the Plan is
approved by the Company's stockholders; (iii) the date on which all Shares
available for issuance under the Plan have been issued as fully vested Shares;
or (iv) the date determined by the Board pursuant to its authority under Section
11.3 of the Plan.

      11.3. Amendment of the Plan. The Board or the Committee may at any time
amend, alter, suspend, or terminate the Plan, without the consent of the
Participants or Beneficiaries. The Company shall obtain stockholder approval of
any Plan amendment to the extent necessary to comply with Applicable Laws.

      11.4. Effect of Amendment or Termination. Except as provided in Section
11.5 of the Plan, no amendment, alteration, suspension, or termination of the
Plan shall impair the rights of any Participant or Beneficiary under an
outstanding Award, unless required to comply with an Applicable Law or mutually
agreed otherwise between the Participant and the Committee; any such agreement
must be in writing and signed by the Participant and the Company. Termination of
the Plan shall not affect the Committee's ability to exercise the powers granted
to it hereunder with respect to Awards granted under the Plan prior to the date
of such termination.

                                      -13-
<PAGE>

      11.5. Adjustments of Awards Upon the Occurrence of Unusual or Nonrecurring
Events. The Committee may, in its sole discretion (but subject to the
limitations and conditions expressly stated in the Plan, such as the limitations
on adjustment of Performance Objectives), adjust the terms and conditions of
Awards during the pendency or in recognition of (a) unusual or nonrecurring
events affecting the Company or an Affiliate (such as a capital adjustment,
reorganization, or merger) or the financial statements of the Company or an
Affiliate, or (b) any changes in Applicable Laws or accounting principles. By
way of example, the power to adjust Awards shall include the power to suspend
the exercise of any Option or Stock Appreciation Right.

                                  ARTICLE 12.
                                 MISCELLANEOUS

      12.1. Authorization of Sub-Plans. The Committee may from time to time
establish one or more sub-plans under the Plan for purposes of satisfying
applicable blue sky, securities, and/or tax laws of various jurisdictions. The
Committee shall establish such sub-plans by adopting supplements to this Plan
containing (i) such limitations as the Committee deems necessary or desirable,
and (ii) such additional terms and conditions not otherwise inconsistent with
the Plan as the Committee shall deem necessary or desirable. All sub-plans
adopted by the Committee shall be deemed to be part of the Plan, but each
sub-plan shall apply only to Participants within the affected jurisdiction and
the Company shall not be required to provide copies of any sub-plans to
Participants in any jurisdiction which is not the subject of such sub-plan.

      12.2. Governing Law. The provisions of the Plan and all Awards made
hereunder shall be governed by and interpreted in accordance with the laws of
the State of Delaware, regardless of the laws that might otherwise govern under
applicable principles of conflicts of laws thereof.

      12.3. Committee Manner of Action. Unless otherwise provided in the bylaws
of the Company or the charter of the Committee: (a) a majority of the members of
a Committee shall constitute a quorum, and (b) the vote of a majority of the
members present who are qualified to act on a question assuming the presence of
a quorum or the unanimous written consent of the members of the Committee shall
constitute action by the Committee. The Committee may delegate the performance
of ministerial functions in connection with the Plan to such person or persons
as the Committee may select.

      12.4. Expenses. The costs of administering the Plan shall be paid by the
Company.

      12.5. Severability. If any provision of the Plan or any Award Agreement is
determined by a court of competent jurisdiction to be invalid, illegal, or
unenforceable in any jurisdiction, or as to any person or Award, such provision
shall be construed or deemed to be amended to resolve the applicable infirmity,
unless the Committee determines that it cannot be so construed or deemed amended
without materially altering the Plan or the Award, in which case such provision
shall be stricken as to such jurisdiction, person, or Award, and the remainder
of the Plan and any such Award shall remain in full force and effect.

      12.6. Construction. Unless the contrary is clearly indicated by the
context, (1) the use of the masculine gender shall also include within its
meaning the feminine and vice versa; (2) the

                                      -14-
<PAGE>

use of the singular shall also include within its meaning the plural and vice
versa; and (3) the word "include" shall mean to include, but not to be limited
to.

      12.7. No Trust or Fund Created. Neither the Plan nor any Award Agreement
shall create or be construed to create a trust or separate fund of any kind or a
fiduciary relationship between the Company (or an Affiliate) and a Participant
or any other person. To the extent that any person acquires a right to receive
payments from the Company (or an Affiliate) pursuant to an Award, such right
shall be no more secure than the right of any unsecured general creditor of the
Company (or the Affiliate, as applicable).

      12.8. Headings. Headings are given to the sections and subsections of the
Plan solely as a convenience to facilitate reference. Such headings shall not be
deemed in any way material or relevant to the construction or interpretation of
the Plan or any provision thereof.

      12.9. Complete Statement of Plan. This document is a complete statement of
the Plan.

                                      -15-
<PAGE>

                                    Appendix

As used in the Plan, the following terms shall have the following meanings:

            (a) "Affiliate" means an entity in which the Company has a direct or
indirect equity interest, whether now or hereafter existing; provided however,
that with respect to an Incentive Stock Option, an Affiliate means a "parent
corporation" (as defined in Section 424(e) of the Code) or a "subsidiary
corporation" (as defined in Section 424(f) of the Code) with respect to the
Company, whether now or hereafter existing.

            (b) "Applicable Laws" means the requirements relating to, connected
with, or otherwise implicated by the administration of long-term incentive plans
under applicable state corporation laws, United States federal and state
securities laws, the Code, any stock exchange or quotation system on which the
Shares are listed or quoted, and the applicable laws of any foreign country or
jurisdiction where Awards are, or will be, granted under the Plan.

            (c) "Award" means, individually or collectively, a grant under the
Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock
Units, or other equity-based awards.

            (d) "Award Agreement" means a written agreement setting forth the
terms and provisions applicable to an Award granted under the Plan. Each Award
Agreement shall be subject to the terms and conditions of the Plan.

            (e) "Beneficiary" means the personal representative of the
Participant's estate or the person(s) to whom an Award is transferred pursuant
to the Participant's will or in accordance with the laws of descent or
distribution.

            (f) "Board" means the board of directors of the Company.

            (g) "Code" means the Internal Revenue Code of 1986, as amended. Any
reference to a section of the Code herein shall be a reference to any
regulations or other guidance of general applicability promulgated under such
section, and shall further be a reference to any successor or amended section of
such section of the Code that is so referred to and any regulations thereunder.

            (h) "Committee" means the Compensation Committee of the Board, which
has been constituted by the Board to comply with the requirements of Rule 16b-3
promulgated under the Exchange Act, Section 162(m) of the Code, and/or other
Applicable Laws.

            (i) "Company" means Clinical Data, Inc., a Delaware corporation, or
any successor thereto.

            (j) "Consultant" means any natural person, including an advisor,
engaged by the Company or an Affiliate to render services to such entity.

            (k) "Director" means a member of the Board.

<PAGE>

            (l) "Disability" means total and permanent disability as defined in
Section 22(e)(3) of the Code.

            (m) "Effective Date" means July 27, 2005; provided that the Plan and
any Awards granted hereunder shall be null and void if the Plan is not approved
by the Company's stockholders before any compensation under the Plan is paid.

            (n) "Employee" means any person who is an employee, as defined in
Section 3401(c) of the Code, of the Company or any Affiliate or any other entity
the employees of which are permitted to receive Incentive Stock Options under
the Code. Neither service as a Director nor payment of a director's fee by the
Company shall be sufficient to constitute "employment" by the Company.

            (o) "Exchange Act" means the Securities Exchange Act of 1934, as
amended.

            (p) "Executive Officer" means an individual who is an "executive
officer" of the Company (as defined by Rule 3b-7 under the Exchange Act) or a
"covered employee" under Section 162(m) of the Code.

            (q) "Fair Market Value" means, with respect to Shares as of any date
the closing sale price per share of such Shares (or the closing bid, if no sales
were reported) as reported in The Wall Street Journal (Northeast edition) or, if
not reported therein, such other source as the Committee deems reliable.

            (r) "Incentive Stock Option" means an Option intended to qualify as
an incentive stock option within the meaning of Section 422 of the Code.

            (s) "Nonstatutory Stock Option" means an Option not intended to
qualify as an Incentive Stock Option.

            (t) "Option" means an option to purchase Shares that is granted
pursuant to Article 5 of the Plan. An Option may be an Incentive Stock Option or
a Nonstatutory Stock Option.

            (u) "Participant" means the holder of an outstanding Award granted
under the Plan.

            (v) "Performance Objective" means a performance objective or goal
that must be achieved before an Award, or a feature of an Award, becomes
nonforfeitable, as described in Section 4.3 of the Plan.

            (w) "Period of Restriction" means the period during which Restricted
Stock, the remuneration underlying Restricted Stock Units, or any other feature
of an Award is subject to a substantial risk of forfeiture. A Period of
Restriction shall be deemed to end when the applicable Award ceases to be
subject to a substantial risk of forfeiture.

            (x) "Restricted Stock" means Shares that, during a Period of
Restriction, are subject to restrictions as described in Article 7 of the Plan.

            (y) "Restricted Stock Unit" means an Award that entitles the
recipient to receive Shares or cash after a Period of Restriction, as described
in Article 8 of the Plan.

<PAGE>

            (z) "Service Provider" means an Employee, Director, or Consultant.

            (aa) "Share" means a share of the Company's common stock.

            (bb) "Stock Appreciation Right" means an Award that entitles the
recipient to receive, upon exercise, the excess of (i) the Fair Market Value of
a Share on the date the Award is exercised, over (ii) a base amount specified by
the Committee which shall not be less than the Fair Market Value of a Share on
the date the Award is granted, as described in Article 6 of the Plan

            (cc) "Tax Year" means the Company's taxable year. If an Award is
granted by an Affiliate, such Affiliate's taxable year shall apply instead of
the Company's taxable year.

            (dd) "Termination of Service" means the date an individual ceases to
be a Service Provider. Unless the Committee or a Company policy provides
otherwise, a leave of absence authorized by the Company or the Committee
(including sick leave or military leave) from which return to service is not
guaranteed by statute or contract shall be characterized as a Termination of
Service if the individual does not return to service within three months; such
Termination of Service shall be effective as of the first day that is more than
three months after the beginning of the period of leave. If the ability to
return to service upon the expiration of such leave is guaranteed by statute or
contract, but the individual does not return, the leave shall be characterized
as a Termination of Service as of a date established by the Committee or Company
policy. For purposes of the Plan and any Award hereunder, if an entity ceases to
be an Affiliate, Termination of Service shall be deemed to have occurred with
respect to each Participant in respect of such Affiliate who does not continue
as a Service Provider in respect of the Company or another Affiliate after such
giving effect to such Affiliate's change in status.<PAGE>

                                                                    Exhibit 10.1

              DRUG PRODUCT PRODUCTION AND CLINICAL SUPPLY AGREEMENT

     THIS AGREEMENT is made and entered into effective as of the 15th day of
August, 2006 (the "Effective Date") by and between:

ALTUS PHARMACEUTICALS, INC., a Delaware corporation, with its principal offices
located at 125 Sidney Street, Cambridge, MA 02139 (hereinafter referred to as
"Altus"); and

ALTHEA TECHNOLOGIES, INC., a Delaware corporation, with a place of business
located at 11040 Roselle Street, San Diego, CA 92121 (hereinafter referred to as
"Althea").

Altus and Althea may be referred to herein individually as a "Party", and
collectively as the "Parties".

     WHEREAS, Altus has formulations and/or know-how related to Drug Product, as
defined below; and

     WHEREAS, Altus wishes to have Althea implement certain upgrades and
modifications to its manufacturing facility and Produce Drug Product, and Althea
wishes to implement such upgrades and modifications and Produce Drug Product for
Altus.

     NOW, THEREFORE, in consideration of the premises and the undertakings,
terms, conditions and covenants set forth below, the Parties hereto agree as
follows:

                                   ARTICLE 1

                                  DEFINITIONS.

1.1  AFFILIATE of a Party shall mean any entity that controls or is controlled
     by such Party, or is under common control with such Party. For purposes of
     this definition, an entity shall be deemed to control another entity if it
     owns or controls, directly or indirectly, at least 50% of the voting equity
     of such other entity (or other comparable interest for an entity other than
     a corporation), or otherwise has the actual ability to direct and control
     the management and business affairs of such other entity.

1.2  ANALYTICAL TESTS shall have the meaning provided in Section 3.5.

1.3  BATCH shall mean the quantity of a Drug Product that (a) is produced
     according to a single manufacturing order during a single manufacturing
     run, and (b) is intended to have uniform character and quality within
     specified limits.

1.4  BULK DRUG SUBSTANCE shall mean the human growth hormone compound that is an
     active ingredient in the Altus product known as ALTU-238 (as more fully
     described in the Project Plan) to be supplied by Altus for use in
     Production of Drug Product.

1.5  CGMP shall mean current Good Manufacturing Practices as defined in the Code
     of Federal Regulations, 21 CFR Parts 210-211 and/or the laws and
     regulations of other applicable countries or jurisdictions.

1.6  CANCELLATION FEES shall mean the fees payable by Altus under Section 6.3 in
     the event that Altus cancels the Production of any Batch of Drug Product
     set forth in the Project Plan, except in the event of a default by Althea.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        1

<PAGE>

1.7  COMPONENTS shall mean all components and materials used by Althea in
     Production of Drug Product under this Agreement, including, without
     limitation, Bulk Drug Substance. Components are listed in the Project Plan,
     such Components identified as Components supplied by Altus ("Altus Supplied
     Components") and Components supplied by Althea ("Althea Supplied
     Components").

1.8  CONFIDENTIAL INFORMATION shall mean all information and data provided by
     one Party to the other Party under this Agreement, but excluding any
     specific portion of such information or data that the receiving Party can
     demonstrate:

               (I)  is disclosed to the recipient by a third person who has the
                    right to make such disclosure;

               (II) is or becomes part of the public domain through no fault of
                    the recipient; or

               (III) the recipient can reasonably establish is independently
                    developed by recipient without use of the information
                    disclosed by the disclosing Party.

1.9  DRUG PRODUCT shall mean Altus' proprietary product known as ALTU-238,
     containing Bulk Drug Substance, in finished dosage form packaged and
     labeled for clinical use only, which is to be Produced by Althea under this
     Agreement.

1.10 EQUIPMENT shall have the meaning provided in Section 3.3.

1.11 FACILITY shall mean Althea's existing manufacturing facility located in San
     Diego, California.

1.12 FDA shall mean the United States Food and Drug Administration or any
     successor entity thereto.

1.13 FD&C ACT shall mean the United States Federal Food, Drug and Cosmetic Act,
     as may be amended from time to time.

1.14 IND shall mean an Investigational New Drug Application, as defined in the
     United States Code of Federal Regulations (21 CFR).

1.15 LABELING shall mean all labels and other written, printed, or graphic
     matter upon: (i) Drug Product or any container, carton, or wrapper utilized
     with Drug Product or (ii) any written material accompanying Drug Product.

1.16 MASTER BATCH RECORD (MBR) shall mean the formal set of instructions for
     Production of Drug Product. The MBR shall be developed and maintained by
     the Parties in accordance with Section 4.3.

1.17 PROCESS shall mean Altus' proprietary manufacturing process for the
     manufacture of Drug Product using the Components.

1.18 PRODUCTION OR PRODUCE shall mean the manufacturing, formulation, filling,
     packaging, inspection, labeling, and testing of Drug Product by Althea
     using the Process.

1.19 PRODUCT REQUIREMENTS shall have the meaning provided in Section 8.1.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        2

<PAGE>

1.20 PRODUCT SPECIFICATIONS shall mean a listing of the analytical testing and
     corresponding Specifications, to be performed on the Bulk Drug Substance
     and Drug Product in connection with the stability program.

1.21 PROJECT PLAN shall mean the attached Schedule 1 documenting the parameters
     for Production of Drug Product, including a statement of work defining the
     scope and assumptions of the project, an agreed-upon timeline based upon
     the project's scope and assumptions, the Specifications to be adhered to in
     Producing the Drug Product, a description of Bulk Drug Product and other
     Altus property to be used in the project, a Quality Management Agreement,
     an agreed upon price quote, packaging and delivery instructions, and sample
     certificates of analysis. The Parties acknowledge that as of the Effective
     Date Schedule 1 is a work in process, and each Party agrees to use
     commercially reasonable and good faith efforts to develop and mutually
     agree upon completed versions of such Schedule as promptly as practicable
     following the Effective Date, and upon such agreement the complete Schedule
     1 shall be attached as part of this Agreement.

1.22 PURCHASE PRICE shall mean the amount to be paid by Altus per Batch of Drug
     Product delivered by Althea conforming to the Specifications, as specified
     in Article 5.

1.23 QUALITY MANAGEMENT AGREEMENT shall mean an agreement executed between the
     Parties as provided in Section 7.3, which shall govern quality issues
     related to Production by Althea of Drug Product.

1.24 REGULATORY AUTHORITY shall mean those agencies or authorities responsible
     for regulation of Drug Product in the United States and overseas. Althea
     shall have no obligation to Produce Drug Product in compliance with the
     requirements of a Regulatory Authority not specified in the applicable
     Project Plan.

1.25 RELEASED EXECUTED BATCH RECORD shall mean the completed batch record and
     associate deviation reports, investigation reports, and certificates of
     analysis created for each Batch of Drug Product.

1.26 SPECIFICATIONS shall mean the complete specifications for the Production of
     Drug Product, including as to primary and secondary packaging, and to the
     extent that Althea is required to test the Bulk Drug Substance, for the
     Bulk Drug Substance, which shall be set forth in Product Specifications and
     the Master Batch Record for Drug Product.

1.27 TERM shall have the meaning provided in Section 6.1.

                                   ARTICLE 2

                               STEERING COMMITTEE

     Promptly after the Effective Date, the Parties will form a Steering
     Committee (composed of two representatives from each Party) that will
     oversee and manage the activities of the Parties contemplated by this
     Agreement. Such Steering Committee will seek to operate by consensus. The
     initial members of the Steering Committee shall be [***] and [***] for
     Altus and [***] and [***] for Althea. The Steering Committee shall meet
     within 30 days to establish an overall governance for the collaboration,
     including appointing any subcommittees as needed. The Steering Committee
     will be responsible for managing any such subcommittees created by the
     Steering Committee, and shall have the ultimate decision-making authority
     as to any matter delegated to a subcommittee. A Party may

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        3

<PAGE>

     change its members of the Steering Committee at its discretion. The
     Steering Committee shall meet by telephone, or as otherwise agreed by the
     Parties, as often as needed to facilitate the efficient conduct of the
     activities contemplated by this Agreement, and each Party shall be
     responsible for the costs of its representatives in participating in
     Steering Committee meetings. For clarity, the Steering Committee (and any
     subcommittee) will not have any right or authority to amend or modify in
     any way the terms of this Agreement.

                                   ARTICLE 3

                   FACILITY MODIFICATIONS; TECHNOLOGY TRANSFER

3.1  FACILITY MODIFICATIONS: For Althea to be able to provide to Altus the Drug
     Product in the timeframes contemplated by the Parties, Althea shall perform
     the specific modifications and upgrades to the Facility, as set forth in
     Schedule 1 to this Agreement. Such upgrades and modifications to the
     Facility shall be completed by Althea in accordance with the timeline set
     forth in Schedule 1 hereto. Notwithstanding the foregoing, Altus
     acknowledges that Althea's ability to perform such Facility upgrades and
     modifications will depend upon Altus timely providing to Althea finalized
     CAD drawings and equipment utility requirements for the Facility, and
     timely delivery of skids, and Altus agrees that Althea will not be
     responsible for delays in completion of such modifications and upgrades
     caused by Altus' delay or failure to provide such CAD drawings and
     equipment utility requirements, by delay in delivery of skids, or by other
     causes to the extent beyond Althea's reasonable control and provided that
     Althea uses diligent, commercially reasonable efforts to avoid any such
     delays despite such causes.

3.2  FACILITIES RESERVATION: Althea shall reserve such equipment, space and
     resources in the Facility (after the above modifications described in
     Section 3.1 are completed) as needed to Produce and supply to Altus [***]
     Batches of Drug Product as contemplated by this Agreement (and to
     accomplish all related tasks as set forth in this Agreement) according to a
     schedule mutually agreed by the Parties in good faith. It is anticipated
     that such reservation would begin consistent with Schedule 1, and provided
     further that if additional Facility time is required for Althea to complete
     Production of the [***] Batches, the Parties shall mutually agree in good
     faith to a modified schedule to accomplish such Production as soon as
     practicable.

3.3  EQUIPMENT VALIDATION: Althea shall conduct the manufacturing equipment
     acceptance and preliminary validation processes (IQ, OQ, PQ and Cleaning
     Validation), all as provided in the Project Plan. Such work shall commence
     as promptly as practicable following the completion of the installation of
     the Equipment (as below). Altus shall provide to Althea (on loan) the
     equipment specified in Schedule 2 hereto (the "Equipment") for
     crystallization and formulation of Drug Product and shall provide support
     to Althea for validation of the Equipment. The Equipment shall remain the
     property of Altus and shall be returned to Altus at the end of this
     Agreement or upon early termination of this Agreement. Following written
     notice by Altus to Althea that the Equipment is subject to a third party
     lien or other encumbrance resulting from a financing arrangement, Althea
     agrees to provide such third party with access to the Equipment as
     necessary for such third party to exercise its rights under such financing
     arrangement. Altus shall be responsible for insuring the equipment against
     loss or damage. Althea shall use commercially reasonable efforts to
     maintain the Equipment in good working order and to avoid damage or harm to
     the Equipment. If Altus or a third party is required to visit the Facility
     to perform service, repair or maintenance of the Equipment, or if such
     service, repair or maintenance requires the purchase of spare parts, Altus
     shall be responsible for the cost thereof (which shall be in addition to
     the payment amounts set forth in this Agreement),

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        4

<PAGE>

     except to the extent that Althea's negligence or willful misconduct or
     other failure to comply with its obligations under this Agreement result in
     the need for such service, repair, maintenance or parts, in which case
     Althea shall bear full responsibility for all such costs and expenses.

3.4  PRODUCTION PROCESS TECHNOLOGY TRANSFER: Altus shall transfer all
     manufacturing know-how and processes controlled by Altus comprising the
     Process as necessary for Althea to manufacture the Drug Product using the
     Process, and Althea shall incorporate such technology into the applicable
     resources in the Facility and shall conduct one [***] buffer run, all as
     provided in the Project Plan. Althea also shall conduct additional buffer
     runs as requested by Altus in writing.

3.5  ANALYTICAL METHODS TECHNOLOGY TRANSFER: Altus shall transfer all analytical
     test methods and know-how controlled by Altus as necessary for Althea to
     conduct the validation, QC/QA, and product release of the Drug Product as
     contemplated in the Project Plan (the "Analytical Tests").

3.6  VALIDATION RUNS: Promptly after completion of the Equipment validation as
     provided in Section 3.3 above, Althea shall conduct validation runs of the
     Equipment and separately of the fill process (which uses Althea equipment),
     in accordance with the jointly agreed upon protocols for such validation
     runs. Each such validation run shall use appropriate [***]. Altus shall
     determine whether each such validation Batch manufactured by Althea and
     delivered to Altus has met the success criteria for the validation run,
     which criteria shall be as established by Altus in agreement with Althea,
     such agreement not to be unreasonably withheld. If a particular validation
     run conducted by Althea fails to meet such criteria, an appropriate
     representative from each Party shall meet and discuss and seek to determine
     the causes of such validation run having failed to meet such criteria, and
     Althea shall use best efforts to rectify any such problems as soon as
     practicable. Althea shall recommence conducting the applicable validation
     run, and shall conduct such validation runs (on each of the Equipment and
     the fill process, until three (3) consecutive validation runs for each the
     particular manufacturing steps (i.e., using the Equipment or using fill
     equipment) have met the applicable criteria.

                                   ARTICLE 4

                           PRODUCTION OF DRUG PRODUCT.

4.1  DRUG PRODUCT MANUFACTURING: After completion of the validation runs as
     provided in Section 3.6, Althea shall Produce the Drug Product in the
     Facility using the Equipment, and such other equipment and resources of
     Althea as are needed to complete such Production. The Drug Product shall be
     manufactured in accordance with cGMP, the Master Batch Record and all other
     applicable laws and regulations and shall conform with the Specifications.
     The Drug Product will be manufactured in [***] Batches: [***] Batches at
     [***] per run and [***] Batch of [***] (but provided that Altus may elect
     to convert one of the [***] Batches into a [***] [***] Batch, on written
     notice and subject to payment of additional Purchase Price as provide in
     Section 5.5). It is agreed that the first Batch will be conducted and
     completed consistent with the applicable timeline in Schedule 1 (subject to
     Section 3.1 above), with the commencement and delivery of such Batch to
     occur on the schedule set forth in Schedule 1 hereto. For the remaining
     Batches, which are expected to be conducted and completed in 2007, Altus
     will provide one month's notice to Althea to schedule the manufacturing
     run(s), and Althea shall commence the manufacturing run within one month of
     such notice. In addition, Altus may request that Althea Produce one or more
     additional Batches of Drug Product in 2007 (at [***] and/or [***] per run,
     as specified by Altus) upon the same advance notice as applicable to the
     first [***] Batches to be Produced in 2007, except that if, at the time of

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        5

<PAGE>

     Altus' request, the skids have been removed from the Facility, then six
     weeks' advance notice will be required. Althea shall complete the
     manufacturing and QA/QC and delivery of the final, completed Drug Product
     in a particular Batch within [***] days of commencing the manufacturing run
     for such Batch. For each Batch that is Produced, the delivered Drug Product
     shall comprise at least an aggregate of [***] pre-filled syringes (for a
     [***] Batch), or [***] pre-filled syringes (for a [***] Batch), meeting the
     Specifications and other obligations of this Agreement. Altus shall have
     the right to inspect each Batch delivered to determine if it meets the
     Specifications and otherwise is conforming, and may reject any Batch that
     fails to meet the Specifications or otherwise is defective. Althea shall
     manufacture and deliver to Altus as soon as possible a new complete Batch
     meeting the Specifications if Altus properly rejects a Batch.

4.2  STABILITY STUDIES: Althea shall conduct stability studies on the Drug
     Product, in accordance with the study protocols as provided in Schedule 5
     hereto. The Parties acknowledge that as of the Effective Date such Schedule
     is a work in process; each Party agrees to use commercially reasonable and
     good faith efforts to develop and mutually agree upon the completed version
     of such Schedule as promptly as practicable following the Effective Date,
     and upon such agreement such completed Schedule shall be attached as part
     of this Agreement.

4.3  DOCUMENTATION: The Master Batch Record shall be prepared, discussed,
     reviewed and approved by Althea and Altus jointly prior to commencement of
     Production. Althea shall not make any change to the Master Batch Record
     without Altus' prior written consent. Each Batch of Drug Product shall be
     Produced by using a copy of the Master Batch Record, and such copy shall be
     assigned a unique batch number applicable to such Batch of Drug Product.
     Such copy of the Master Batch Record for a particular Batch shall record
     all applicable information relating to the Production of the Drug Product
     in such Batch in the form specified by the Master Batch Record, including
     any deviation from the manufacturing process specified in the Master Batch
     Record and the results of all quality control and quality assurance testing
     performed in such Production. Althea shall ensure that all information
     required by the Master Batch Record relating to the Production of a Batch
     shall be completely and accurately recorded and documented in the copy of
     the Master Batch Record applicable to such Batch. The final, complete
     Master Batch Record for a particular completed Batch shall be the Released
     Executed Batch Record. Upon delivery of a completed Batch, Althea shall
     provide to Altus the Released Executed Batch Record for such Batch and any
     additional required documentation to support Production in a form
     reasonably suitable for Altus' submission to the FDA.

4.4  COMPONENT SUPPLY: Althea shall be responsible for procuring, testing and
     releasing on a timely basis all Components (including BD syringes, except
     as otherwise provided below) needed to Produce and deliver the Drug
     Product, except that Altus shall supply to Althea, at Altus' cost, the
     Altus Supplied Components. Except as may specifically be set forth in the
     Project Plan, on receipt of the Altus Supplied Components as set forth
     above, Althea's sole obligation with respect to evaluation of the Altus
     Supplied Components shall be to review the accompanying certificate(s) of
     analysis (if any) to confirm that the Altus Supplied Components conform
     with the Specifications. [***]Althea [***] in order to [***] of the batches
     of Drug Product, the Parties will[***] [***] [***] As promptly as
     practicable after the Effective Date, Althea will inform Altus of the
     quantity of BD syringes that Althea anticipates it will need. In addition,
     Althea will as promptly as practicable provide an approved vendor list for
     its purchase of all needed Althea Supplied Components, [***] that relate to
     Althea Supplied Components for Altus' review. If Altus determines that
     additional audits of vendors of Althea Supplied Components need to be
     conducted, such needed vendor audits will be conducted by the Parties
     [***].

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        6

<PAGE>

4.5  COMPONENT DELIVERY DELAYS: Althea shall have no responsibility for delays
     in delivery of Drug Product caused by delays in receipt of Altus Supplied
     Components. If Althea receives the Altus Supplied Components from Altus
     with less time than requested in the applicable Project Plan prior to the
     scheduled date of Production of a particular Batch of Drug Product, and as
     a result Althea does not have sufficient time to Produce such Drug Product
     by the scheduled date as reasonably determined by Althea, then Althea and
     Altus shall discuss and agree on a rescheduled date for commencement and
     completion of Production of such Batch of Drug Product and on a reasonable
     rescheduling fee to be paid by Altus to compensate Althea for the delay.

4.6  IMPORTER OF RECORD: In the event any material or equipment to be supplied
     by Altus, including without limitation Altus Supplied Components, is
     imported into the United States for delivery to Althea ("Imported Goods"),
     Altus shall be the "Importer of Record" of such Imported Goods. As the
     Importer of Record, Altus shall be responsible for all aspects of the
     Imported Goods including, without limitation (a) customs and other
     regulatory clearance of Imported Goods, (b) payment of all tariffs, duties,
     customs, fees, expenses and charges payable in connection with the
     importation and delivery of the Imported Goods, and (c) keeping all
     records, documents, correspondence and tracking information required by
     applicable laws, rules and regulations arising out of or in connection with
     the importation or delivery of the Imported Goods.

4.7  MATERIAL SAFETY DATA SHEET: Altus shall provide Althea a Material Safety
     Data Sheet for Bulk Drug Substance and for Drug Product. Althea shall
     immediately notify Altus of any unusual health or environmental occurrence
     relating to Drug Product, including, but not limited to any claim or
     complaint by any employee of Althea or any of its Affiliates or third party
     that the operations of Althea pursuant to this Agreement have resulted in
     any adverse health or safety effect on an employee or third party. Althea
     agrees to advise Altus immediately of any safety or toxicity problems of
     which it becomes aware regarding the Drug Product.

4.8  VENDOR AND SUPPLIER AUDIT AND CERTIFICATION: Altus shall certify and audit,
     as per its standard practice, all vendors and suppliers related to Altus'
     purchase of Altus Supplied Components, and shall have the right to approve
     Althea's selection of vendors and suppliers for Althea Supplied Components.

4.9  DELIVERY TERMS: Althea shall ship all finished Drug Product to Altus or to
     Altus' designated consignee. All shipments shall be shipped FCA the
     Facility, by a common carrier designated by Altus, at Altus' expense;
     provided, however, that Althea shall be responsible for the loading of the
     Drug Product on departure and shall bear risk of loss and all costs of such
     loading. Altus shall procure, at its cost, insurance covering damage or
     loss of Drug Product during shipping. All shipping instructions of Altus
     shall be accompanied by the name and address of the recipient and the
     shipping date.

4.10 EXPORTER OF RECORD: Altus shall be the exporter of record for any Product
     shipped out of the United States, as Altus remains the owner of the
     Product. Altus warrants that all shipments of Product exported from the
     United States will be made in compliance with all applicable United States
     export laws and regulations and all applicable import laws and regulations
     into the country of deportation. Altus shall be responsible for obtaining
     and paying for any licenses or other governmental authorization(s)
     necessary for the exportation from the United States. Altus shall select
     and pay the freight forwarder who shall solely be Altus' agent. Altus and
     its freight forwarder shall be solely responsible for preparing and filing
     the Shipper's Export Declaration and any other documentation required for
     the export.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        7

<PAGE>

4.11 RETURNS: Drug Product returned by third parties is the responsibility of
     Altus, but subject to Section 4.1 with respect to defective Drug Product.

4.12 COMMERCIAL SUPPLY: Commencing on the written request by Altus, the Parties
     shall negotiate in good faith the terms of a commercial supply agreement
     under which Althea shall manufacture and supply to Altus final ALTU-238
     product containing Bulk Drug Substance for commercial sale by Altus (the
     "Commercial Supply Agreement"), which agreement shall be on commercially
     reasonable terms as negotiated in good faith. The Parties shall use good
     faith efforts to complete such negotiations and enter into the Commercial
     Supply Agreement as soon as practicable after Altus' notice, and in any
     event within 45 days of such notice. In the event that, during the term of
     this Agreement or within one (1) year after its expiration or termination
     (except in the case of termination as a result of Althea's uncured material
     breach), Altus has not entered into the Commercial Supply Agreement and
     instead Altus enters into an agreement or arrangement under which a third
     party is granted the right to manufacture, formulate, fill, package and
     label Altus' proprietary product known as ALTU-238 for commercial sale,
     then Altus shall, within 10 days after entering into such agreement or
     arrangement, notify Althea thereof in writing [***] needed to perform the
     services under this Agreement. Altus acknowledges that entering into this
     Agreement will require substantial investment by Althea and will require
     that Althea forego other potential opportunities, and Altus hereby agrees
     that the foregoing fee is reasonable in principle and in amount.

                                   ARTICLE 5

                                 FINANCIAL TERMS

5.1  FACILITY MODIFICATIONS PAYMENT: Althea acknowledges receipt of payment from
     Altus of $[***] in consideration of Althea undertaking and completing the
     Facility modifications as contemplated in Section 3.1 above and Althea
     reserving Facility time as provided in Section 3.2 above.

5.2  VALIDATION PAYMENTS: In consideration of the IQ, OQ and PQ validation work
     under Section 3.3, Altus shall pay Althea the sum of $[***], which shall be
     due and payable as follows: (a) $[***] within 30 days of receipt of an
     invoice provided after the Effective Date; (b) $[***] within 30 days after
     receipt of an invoice from Althea provided after the completion of such
     validation work, and delivery to Altus of the draft validation report, and
     (c) $[***] within 30 days after receipt of an invoice from Althea [***]. In
     consideration of the Cleaning Validation work under Section 3.3, Altus
     shall pay Althea the sum of $[***], which shall be due and payable as
     follows: (a) $[***] within 30 days of receipt of an invoice provided after
     the Effective Date; (b) $[***] within 30 days after receipt of an invoice
     from Althea provided after the completion of the first two manufacturing
     Batches and their respective cleaning validation work, and (c) $[***]
     within 30 days after receipt of an invoice from Althea provided after
     completion of manufacturing Batches and respective cleaning validation work
     [***]. Althea will replace a failed equipment validation Batch at its cost
     if such failure is caused by Althea's failure to conform to the Master
     Batch Record or other negligence of Althea in performance of the Process.
     If failure is not determined to be caused by Althea's failure as described
     above then replacement validation runs will be at Altus cost. In
     consideration of the 3 media fill validation runs under Section 3.6 (i.e.,
     validation runs using the Althea fill equipment), Altus shall pay Althea
     the sum of $[***] per fill run including all raw materials, which shall be
     due and payable as follows: $[***] within 30 days after of receipt by Altus
     of an invoice provided by Althea 30 days prior to the scheduled
     commencement of each run, and $[***] within 30 days after receipt of an
     invoice by Altus [***]. If a fill validation run fails, Althea will rerun
     at the validation run at its cost (including raw materials).

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        8

<PAGE>

5.3  PROCESS TRANSFER PAYMENT: In consideration of the process technology
     transfer work under Section 3.4, Altus shall pay Althea the sum of $[***],
     which shall be due and payable as follows: (a) $[***] within 30 days of
     receipt of an invoice provided after the Effective Date; (b) $[***] within
     30 days after receipt of an invoice from Althea provided after the
     completion of the first buffer run after such process technology transfer
     work is completed and the delivery to Altus of the draft report, and (c)
     $[***] within 30 days after receipt of an invoice from Althea provided
     after the completion of all such process technology transfer work [***].
     Further, Altus shall pay Althea $[***] for each additional buffer run at
     [***] scale that is requested by Altus for assurance, which shall be due
     and payable as follows: (i) $[***] within 30 days after receipt of an
     invoice from Althea provided after Altus' request for such additional
     buffer run; and (ii) $[***] within 30 days after receipt of an invoice from
     Althea provided after the completion of such buffer run [***] by Althea.

5.4  ANALYTICAL METHODS TRANSFER PAYMENT: In consideration of the analytical
     methods transfer work under Section 3.5, Altus shall pay Althea the sum of
     $[***], which shall be due and payable as follows: (a) $[***] within 30
     days after the Effective Date; (b) $[***] within 30 days after receipt of
     an invoice from Althea provided after the completion of the technical
     activity of assay qualification, and (c) $[***] within 30 days after
     receipt of an invoice from Althea provided after the completion of such
     analytical methods transfer work [***] by Althea.

5.5  TRANSFER PRICES FOR DRUG PRODUCT: In consideration of the Production of a
     Batch in accordance with Section 4.1, Altus shall pay Althea the sum of
     $[***] (whether such Batch results from a [***] or [***] run), which shall
     be due and payable as follows: (a) $[***], payable within 30 days after
     receipt of an invoice from Althea provided after the Effective Date for the
     first Batch, and within 30 days of receipt of an invoice from Althea
     provided after Altus ordering each successive Batch thereafter; and (b)
     $[***] within 30 days after receipt of an invoice from Althea provided
     after completion by Althea of delivery of such Batch acceptance of such
     Batch by Altus (under terms of Section 8.1). Notwithstanding the foregoing,
     if Altus elects (as provided in Section 4.1) to convert one of the [***]
     Batches to a [***] Batch, then the payment amount for such [***] Batch
     shall be a sum of $[***] due and payable as follows: (a) $[***], payable
     within 30 days after receipt of an invoice from Althea provided after Altus
     makes such election; (b) $[***] within 30 days after receipt of an invoice
     from Althea provided after completion by Althea of delivery of such Batch
     and acceptance of such Batch by Altus (under terms of Section 8.1).

5.6  STABILITY STUDIES PAYMENT: In consideration of the stability studies work
     under Section 4.2 on each Batch (including delivery of the final report to
     Altus) as requested by Altus, Altus shall pay Althea the sum of $[***],
     which shall be due and payable as follows: (a) $[***] within 30 days after
     receipt of an invoice from Althea provided after initiation of protocol
     drafting for such studies; (b) $[***] within 30 days after receipt of an
     invoice from Althea provided after completion of the last sample point for
     the stability study for the second batch; and (c) $[***] within 30 days
     after receipt of an invoice from Althea [***].

5.7  SUCCESS BONUS PAYMENT: Altus shall pay Althea a success bonus payment in
     the amount of $[***], within 30 days after receipt of an invoice provided
     by Althea after successful completion and delivery, in accordance with the
     mutually agreed upon timeline in Schedule 1, of the first Batch that meets
     the Specifications. Any modifications to such timeline must be agreed upon
     in writing by both Parties.

5.8  LATE PAYMENTS: Late payments shall accrue interest from the due date at the
     rate of 1.0% per month; provided, however, that in no event shall such rate
     exceed the maximum legal annual interest

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                        9

<PAGE>

     rate. Notwithstanding the foregoing, if Altus disputes in good faith that a
     particular payment hereunder is due, Altus shall provide prompt written
     notice thereof to Althea, and the Parties shall promptly discuss such
     dispute in good faith and use all reasonable efforts to resolve such
     dispute as promptly as practicable. No interest shall accrue hereunder on
     amounts that are subject to good faith dispute between the Parties for so
     long as such dispute continues. The payment of interest hereunder shall not
     limit Althea from exercising any other rights it may have as a consequence
     of the lateness of any payment.

5.9  MANNER AND PLACE OF PAYMENT: All payments by Altus, as specified above,
     shall be subject to Althea delivering to Altus by electronic mail an
     invoice in the amount owed in accordance with the above provisions, and the
     payment shall be made within the applicable number of calendar days (as
     specified in the particular payment provision) after the date Altus
     receives the applicable invoice. All such electronic mail invoices shall be
     sent to the following e-mail address (or such other e-mail address as Altus
     may specify in writing to Althea): [***]. All payments under this Article 5
     shall be made by check or wire transfer in immediately available funds to
     the following account:

               Althea Technologies, Inc.
               11040 Roselle Street
               San Diego CA 92121-1205
               Ph. 858-882-0123

               Comerica Bank
               11943 El Camino Real
               San Diego CA 92130
               SWIFT#: [***]
               TRANSIT#: [***]
               ACCOUNT#: [***]

5.10 REMAINING COMPONENTS: Within 30 days of completion of the final quality
     control release and final invoice and of delivery of the final completed
     Batch, Altus will instruct Althea as to whether to return or dispose of all
     of the remaining Components provided by Altus. If Althea does not receive
     notice from Altus, Althea will have the right to use or dispose of any such
     remaining Components.

5.11 DEFAULT IN PAYMENT OBLIGATIONS: In addition to all other remedies available
     to Althea in the event of a Altus default, if Altus fails to make payments
     as required hereunder, Althea may take appropriate measures to assure
     prompt and full payment, including refuse to Produce any Drug Product until
     Altus' account is paid in full, modify the foregoing terms of payment,
     place the account on a letter of credit basis, require full or partial
     payment in advance, suspend deliveries of Drug Product until Altus provides
     assurance of performance reasonably satisfactory to Althea, and/or take
     other reasonable means as Althea may determine.

5.12 FORMAT OF REPORTS: For any payment obligation of Altus under this Article 5
     that is contingent upon Altus' acceptance of a draft or final report
     delivered by Althea, the parties shall mutually agree in advance on the
     format of such report, and Altus shall not unreasonably withhold or delay
     its acceptance of any such report delivered by Althea that conforms to the
     agreed-upon format.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       10

<PAGE>

                                    ARTICLE 6

                              TERM AND TERMINATION.

6.1  TERM: This Agreement shall commence on the date first above written and
     will continue until the Production and delivery of all [***] Batches, as
     described in the Project Plan, has been completed in accordance with this
     Agreement, unless sooner terminated pursuant to Section 6.2 herein (the
     "Term").

6.2  TERMINATION: This Agreement may be terminated at any time upon the
     occurrence of any of the following events:

     6.2.1 TERMINATION FOR BREACH: A Party may terminate this Agreement upon the
          material breach of any provision of this Agreement by the other Party
          if such breach is not cured by the breaching Party within 30 calendar
          days (or such additional time reasonably necessary to cure such
          default provided the breaching Party has commenced a cure within the
          30-day period and is diligently pursuing completion of such cure)
          after receipt by the breaching Party of written notice of such breach.
          At the option of the non-breaching Party, such termination may be with
          respect to the entire Agreement, or only with respect to the Batch of
          Drug Product that is subject to the breach.

     6.2.2 TERMINATION FOR FINANCIAL MATTERS: This Agreement may be terminated
          immediately by a Party by giving the other Party written notice
          thereof in the event such other Party makes a general assignment for
          the benefit of its creditors, or proceedings of a case are commenced
          in any court of competent jurisdiction by or against such Party
          seeking (a) such Party's reorganization, liquidation, dissolution,
          arrangement or winding up, or the composition or readjustment of its
          debts, (b) the appointment of a receiver or trustee for or over such
          Party's property, or (c) similar relief in respect of such Party under
          any law relating to bankruptcy, insolvency, reorganization, winding up
          or composition or adjustment of debt, and such proceedings shall
          continue undismissed, or an order with respect to the foregoing shall
          be entered and continue unstated, for a period of more than 60 days.

6.3  PAYMENT ON TERMINATION: In the event of cancellation by Altus of the
     Production of any Batch set forth in a Project Plan or of the early
     termination of this Agreement, Altus shall make the following payments to
     Althea: (a) [***] Althea for the [***] by Althea for [***] and not already
     [***], and for which such [***] Althea [***] Altus on such [***]; (b) [***]
     Althea for the [***]Althea for [***] Altus [***] Althea not to [***] under
     subsection (a) above; (c) reimburse Althea for the actual out-of-pocket
     amounts incurred (up to ceasing Production) for all Batch work-in-process
     commenced by Althea on Drug Product being manufactured, but after deducting
     the actual amounts already paid by Altus (as to such work-in-progress)
     under Section 5.5; and (d) complete payment for all finished Drug Product
     delivered by Althea and meeting the Specifications. Following expiration or
     termination, Althea shall ship to Altus all remaining Components and any
     other materials supplied by Altus, at Altus' cost and per Altus'
     instructions. Altus shall make payment for all expenses described in
     Section 6.3 within 30 days of the invoice date, provided that Althea
     provides Altus with all appropriate documentation and back-up for such
     invoices.

6.4  SURVIVAL: Termination, expiration, cancellation or abandonment of this
     Agreement through any means or for any reason, except as set forth in
     Section 15.1, shall be without prejudice to the rights and remedies of
     either Party with respect to any antecedent breach of any of the provisions
     of this

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       11
<PAGE>

     Agreement. The provisions of Sections 4.12, 5, 6, 12, 13, 14, 15, 16, 17
     and 18 hereof shall survive expiration or termination of this Agreement.

                                   ARTICLE 7

             CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE.

7.1  CERTIFICATES OF ANALYSIS: At Althea's cost and expense, Althea shall test,
     or cause to be tested by third parties, in accordance with the
     Specifications each Batch of Drug Product that is Produced pursuant to this
     Agreement, such testing to be completed before delivery of the Batch to
     Altus or its designee. All results of such testing shall be recorded in a
     certificate of analysis in a form approved by Altus or its designee (each,
     a "Certificate of Analysis"). Althea shall deliver to Altus or its
     designee, prior to each completed Batch being delivered, the completed
     Certificate of Analysis for such Batch, which shall set forth the items
     tested and the test results. Althea shall also indicate on the final page
     of the Executed Release Batch Record for each Batch delivered that all
     batch Production and control records have been reviewed and approved by the
     appropriate quality control unit. Althea shall send, or cause to be sent,
     to Altus or its designee such Certificate of Analysis and Executed Release
     Batch Record for each Batch prior to the shipment of the Batch of Drug
     Product. Altus or its designee shall have the right to test, or cause to be
     tested, for final release, each Batch of Drug Product as meeting the
     Specifications and other requirements of this Agreement. As required by the
     FDA (see Section 7.2 below), Altus (or its designee, as applicable) assumes
     full responsibility for final release of each Batch of Drug Product.

7.2  MANUFACTURING COMPLIANCE: Althea shall advise Altus immediately if an
     authorized agent of any regulatory body visits Althea's manufacturing
     facility and makes an inquiry regarding Althea's Production of Drug Product
     for Altus. Manufacturing deviations and investigations which occur during
     Production of Drug Product and which do not cause the Production to be
     non-compliant with cGMP, shall not be deemed to cause such Drug Product to
     be non-conforming.

7.3  QUALITY AGREEMENT: The responsibilities of the quality units of each Party
     related to the Production of all Drug Product shall be described in a
     quality agreement between the Parties, substantially in accordance with
     industry standards (the "Quality Agreement"). The Parties agree to
     negotiate and execute the Quality Agreement within ninety (90) days
     following the Effective Date (or such other period of time as may be
     mutually agreed by the Parties). Such responsibilities shall include: (i)
     the specific content of the Certificate of Analysis, including without
     limitation the certificate of conformance, (ii) the nature of the Batch
     record review process, including notification of deviations associated with
     the Process or Specifications, (iii) a table of key contacts associated
     with the manufacturing, regulatory, quality control and quality assurance
     functions; and (iv) maintenance of distribution records that contain all of
     the appropriate information as specified in cGMP; and (v) other appropriate
     quality matters, such responsibility for maintaining reserve samples
     pursuant to cGMP.

7.4  CUSTOMER COMPLAINTS: Altus, as required by cGMP, shall maintain complaint
     files. All specific Altus Drug Product-related complaints received by
     Althea shall be forwarded to Altus. Altus shall be responsible for the
     review of the complaint to determine the need for an investigation or the
     need to report to the FDA as required by cGMP. Altus shall send to Althea
     all Drug Product performance or manufacturing-related complaints which
     require investigation. Althea shall conduct an investigation for each Drug
     Product performance or manufacturing-related complaint and shall report

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       12

<PAGE>

     findings and follow-up of each investigation to Altus. Altus shall make
     these complaint files available to Althea in the event they are required
     during an FDA inspection.

7.5  INSPECTIONS AND PRODUCTION OVERSIGHT: Altus or its designee, upon prior
     written notice and during normal business hours, shall have the right to
     inspect, as reasonably needed and for not more than two (2) days, the
     Althea Master Batch Records for each Batch, all other relevant documents
     relating to Production, and the portions of Althea's facility used for
     Production of Drug Product, and Althea shall provide full cooperation and
     assistance in such audit. If Altus or its designee chooses to audit Althea
     more than one time in a calendar year or for more than two (2) days, and
     Altus does not have a reasonable reason for conducting such additional
     audit or additional day(s) of audit, Althea may require that Altus or its
     designee reimburse Althea for Althea's reasonable expenses incurred in
     hosting such additional audit or such additional day(s) of auditing. All
     audited data will be treated as Confidential Information of Althea, and
     neither Altus nor its designee shall be permitted to remove or copy data
     without Althea's prior consent, such consent not to be unreasonably
     withheld. In addition, Althea shall permit any regulatory agency to
     inspect, as reasonably requested or needed, that portion of the Facility
     where Drug Product is manufactured or stored and to review all Althea
     documents relating to Drug Product Production or storage as is reasonably
     necessary for the purpose of assessing Althea's compliance with the
     Process, cGMP, the Specifications, all other applicable law and regulatory
     standards, and applicable chemical manufacturing controls. In addition,
     Altus or its designee shall have the right to have an employee or agent
     present at the Facility during the preparation for or conduct of any
     Production run for a Batch of Drug Product, and such employee or agent
     shall be free to inspect and oversee all aspects of such preparation or
     Production run and to comment to Althea thereupon. Althea shall provide
     such employee or agent of Altus or its designee suitable office space
     equipped with a phone line and high-speed internet connection and other
     standard office equipment and supplies as needed, for use by such employee
     or agent in conducting the inspection and oversight activities during such
     Production run. Althea shall have the right to require that Altus or its
     designee first execute a commercially reasonable and typical confidential
     disclosure agreement.

7.6  REGULATORY COMPLIANCE: Prior to commencing production of Drug Product,
     Althea shall: (a) ensure that the Facility meets all requirements of cGMP
     and all other applicable laws and regulations; and (b) obtain (and
     thereafter during the term of the Agreement maintain) for the Facility, at
     its sole cost, all permits, licenses and approvals (including facilities
     licenses) needed for Althea to be able to Produce and supply the Drug
     Product. Althea shall use commercially reasonable efforts to resolve as
     soon as possible any issues affecting Drug Product that arise in its
     seeking or maintaining any such facilities licenses, or other needed
     permits and approvals, including completely addressing and rectifying any
     deviations or other issues affecting Drug Product raised in any Warning
     Letter from the FDA or any similar warning or objection by a regulatory
     authority, subject to the provisions of Section 11.2 hereof. Except as set
     forth above in this Section 7.6, Altus shall be solely responsible for
     compliance with applicable laws and regulations with respect to the use and
     distribution of Drug Product, including, without limitation, all contact
     with the FDA regarding the foregoing. Althea shall reasonably cooperate
     with and assist Altus in all regulatory filings and interactions as Altus
     may make with regards to the Drug Product, including providing any
     information in Althea's control needed for such applications, filings or
     activities and any additional support relating to Drug Product as
     reasonably requested by Altus.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       13

<PAGE>

                                   ARTICLE 8

                           ACCEPTANCE OF DRUG PRODUCT.

8.1  NON-CONFORMING DRUG PRODUCT: Within 30 calendar days after receipt by Altus
     of a particular Batch, or 15 calendar days after receipt by Altus of the
     Released Executed Batch Record for a delivered Batch, whichever is later,
     Altus shall use reasonable efforts to determine whether Drug Product in the
     Batch conforms to the Specifications, the Master Batch Record, the Process,
     and the Project Plan (collectively the "Product Requirements").

     8.1.1 If Altus determines that the particular Batch of Drug Product
          conforms to the Product Requirements, Altus shall give Althea written
          notice of such determination and Altus shall be deemed to have
          accepted the Drug Product and waived its right to revoke acceptance
          [***]

     8.1.2 If Altus does not give notice that a particular Batch fails to
          conform to the Product Requirements within the time frame specified
          above, then Altus shall be deemed to have accepted the Drug Product
          and waived its right to revoke acceptance [***].

     8.1.3 If Altus believes any Batch of Drug Product does not conform to the
          Product Requirements and that such failure to conform was caused by
          either (i) Althea's failure to conform to the Master Batch Record or
          other negligence of Althea in the performance of the Process, or (ii)
          [***] of such Drug Product (either case, an "Althea Fault"), then
          Altus shall notify Althea by telephone, including a detailed
          explanation of the non-conformity and the basis for Altus' belief that
          it was caused by an Althea Fault, and shall confirm such notice in
          writing via facsimile, email or overnight delivery to Althea. [***]
          Upon receipt of such notice, Althea will investigate such alleged
          non-conformity using good faith commercially reasonable efforts. If
          Althea determines that such Drug Product is non-conforming as a result
          of an Althea Fault, Althea shall notify Altus of such determination
          promptly and the Parties shall proceed under Section 8.2. If Althea
          disagrees with Altus' determination that the Batch of Drug Product is
          non-conforming as a result of Althea Fault, Althea shall so notify
          Altus by telephone, no later than 30 days after the notice from Altus,
          and shall confirm such notice in writing by facsimile, email or
          overnight delivery, and the Parties shall proceed under Section 8.1.4.

     8.1.4 For any dispute by the Parties as to whether a particular Batch of
          Drug Product is conforming or non-conforming with the Product
          Requirements, and/or whether such non-conformity resulted from Althea
          Fault, samples of the Batch of Drug Product, and the relevant Batch
          records and other related documentation, will be submitted to a
          mutually acceptable laboratory or consultant for resolution, whose
          determination of conformity or non-conformity, and the cause thereof
          if non-conforming, shall be binding upon the Parties (absent fraud or
          gross negligence). Altus shall bear the costs of such laboratory or
          consultant, except as set forth in Section 8.2.

8.2  REMEDIES FOR NON-CONFORMING PRODUCT: [redactions in this section TBD] With
     respect to any Batch that Althea agrees is non-conforming, or that the
     laboratory or consultant determines is non-conforming (as provided in
     Section 8.1.4), due to an Althea Fault, Althea shall Produce at its cost
     and as soon as possible a replacement Batch of Drug Product (in the amount
     of the Batch that was non-conforming (that is, [***] or [***], as
     applicable), with Althea paying for all materials required

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       14

<PAGE>

     to Produce such replacement Batch including needed amounts of the Altus
     Supplied Components [***] Altus shall have the same rights as above to
     inspect and accept (or reject, if applicable) such replacement Batch. With
     respect to a Batch that is non-conforming to the Product Requirements but
     where such non-conformity is not due to an Althea Fault, Althea shall if
     requested by Altus manufacture a replacement Batch of Drug Product, [***]
     as provided in Section 5.6, as soon as practicable.

8.3  NON-CONFORMING BULK DRUG SUBSTANCE: Notwithstanding the foregoing, if a
     Batch of Drug Product is rejected by Altus, and such Batch's failure to
     meet the Product Requirements is due to the Bulk Drug Substance in such
     Batch being non-conforming with applicable specifications at the time of
     delivery by Altus of such Bulk Drug Substance to Althea, then Altus shall
     not be permitted to reject such Batch (for purposes of payment), but Althea
     shall use reasonable efforts to Produce a conforming replacement Batch on a
     reasonable schedule agreed to by the Parties (with Altus supplying at its
     cost the amounts of Altus Supplied Components for such Products, and Altus
     paying all amounts under Section 5.6 for such replacement Batch).

                                   ARTICLE 9

                              DRUG PRODUCT RECALLS.

9.1  DRUG PRODUCT RECALLS: In the event Altus shall be required to recall any
     Drug Product because such Drug Product may violate local, state or federal
     laws or regulations, the laws or regulations of any applicable foreign
     government or agency or the Product Specifications, or in the event that
     Altus elects to institute a voluntary recall, Altus shall be responsible
     for coordinating such recall. Altus promptly shall notify Althea if any
     Drug Product is the subject of a recall and provide Althea with a copy of
     all documents relating to such recall. Althea shall cooperate with Altus
     and provide Altus all reasonable assistance in connection with any recall,
     at Altus' expense. Altus shall be responsible for all of the costs and
     expenses of such recall, including Althea's actual out-of-pocket costs in
     providing assistance; except as otherwise provided in the following. [***]
     Althea that[***] Althea (but [***], Althea [***] Altus, [***] that was the
     [***] [***]

                                   ARTICLE 10

                        FORCE MAJEURE; FAILURE TO SUPPLY.

10.1 FORCE MAJEURE EVENTS: Failure of either Party to perform under this
     Agreement (except the obligation to make payments) shall not subject such
     Party to any liability to the other if such failure is caused by acts of
     God, acts of terrorism, fire, explosion, flood, drought, war, riot,
     sabotage, embargo, strikes or other labor trouble, compliance with any
     order or regulation of any government entity, or by any cause beyond the
     reasonable control of the affected Party, whether or not foreseeable,
     provided that written notice of such event is promptly given to the other
     Party.

10.2 FAILURE TO SUPPLY: If Althea fails to supply all or any material part of
     Drug Product ordered by Altus on a timely basis, in accordance with the
     schedule agreed to by the Parties or in the Project Plan, Althea shall use
     commercially reasonable efforts to supply such amounts of undelivered Drug
     Product as soon as possible. Altus may require Althea to initiate
     Production of a new Batch of Drug Product in order to supply the
     undelivered Drug Product at date specified by Altus, and Altus shall have
     the right to have an Altus employee or representative present in the
     preparation for and conduct of the Production of the Batch as needed to
     deliver such Drug Product to Altus. The provisions of

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       15

<PAGE>

     this Section 10.2 shall be without prejudice to Altus' rights under Section
     6.2 and remedies provided for thereunder.

                                   ARTICLE 11

                             CHANGES IN PRODUCTION.

11.1 CHANGES TO MASTER BATCH RECORDS AND PRODUCT SPECIFICATIONS: Althea agrees
     to inform Altus within 15 days of the result of any regulatory development
     or changes that Althea believes may materially affect the Production of
     Drug Product. Althea shall not make any changes to the Master Batch Record
     or the Specifications or Product Specifications without the prior written
     consent of Altus.

11.2 PRODUCT-SPECIFIC CHANGES: If facility, equipment, process or system changes
     are required of Althea in order to Produce the Drug Product as a result of
     requirements set forth by the FDA or any other Regulatory Authority
     ("Required Regulatory Changes"), and such Required Regulatory Changes apply
     primarily to the Production and supply of the Drug Product, then Altus and
     Althea will review such requirements and the necessary changes (including
     costs for such changes), and shall (unless Altus elects to terminate the
     Agreement) agree in writing to the details of such Required Regulatory
     Changes. Althea shall implement such agreed changes as soon as practicable,
     and Altus shall bear 100% of the reasonable costs of such agreed changes.

11.3 GENERAL CHANGES: If any such Required Regulatory Changes apply generally to
     one or more Drug Product as well as to other products manufactured by
     Althea for itself or for third parties, then Altus shall pay a pro rata
     amount of the reasonable cost of such Required Regulatory Changes based
     upon the proportion of time that such facility is dedicated to the
     Production of Drug Product relative to the manufacture of such other
     products.

                                   ARTICLE 12

                                CONFIDENTIALITY.

12.1 CONFIDENTIALITY: It is contemplated that in the course of the performance
     of this Agreement each Party may, from time to time, disclose Confidential
     Information to the other. Each Party agrees (a) to take all reasonable
     steps to prevent disclosure of Confidential Information of the other Party
     to third parties, and (b) not to use the Confidential Information of the
     other Party except in order to accomplish the purposes of this Agreement.
     No provision of this Agreement shall be construed so as to preclude Altus'
     disclosure of Confidential Information as may be reasonably necessary to
     secure from any governmental agency necessary approvals or licenses or to
     obtain patents with respect to the Drug Product. Althea understands and
     agrees that the Master Batch Records, the Executed Released Batch Records,
     and all other information directly relating to the Production and supply of
     Drug Product is and shall be the Confidential Information of Altus
     (regardless that Althea disclosed such information, data and records to
     Altus).

12.2 PRIOR CONFIDENTIALITY AGREEMENT: This Agreement, by reference, incorporates
     the Confidentiality Agreement signed by Altus and Althea on October 4,
     2005, and is made a part hereof as though fully set forth herein.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       16

<PAGE>

12.3 THIRD PARTY DISCLOSURE: Althea shall be permitted to disclose Drug Product
     information to third party developmental and analytical service providers
     in connection with performance of its obligations hereunder provided such
     providers shall be subject to confidentiality agreements no less stringent
     than the obligations in this Agreement. A Party may disclose Confidential
     Information of the other Party to those of its Affiliates, agents and
     consultants who need to know such information to accomplish the purposes of
     this Agreement (collectively, "Permitted Recipients"); provided such
     Permitted Recipients are bound to maintain such Confidential Information in
     confidence and not to use such Confidential Information except as necessary
     to accomplish such purposes.

12.4 LITIGATION AND GOVERNMENTAL DISCLOSURE: Notwithstanding the above
     obligations, a Party may disclose the Confidential Information of the other
     Party to the extent such disclosure is reasonably necessary for prosecuting
     or defending litigation, complying with applicable governmental laws or
     regulations, or as required to comply with court orders, provided that if a
     Party is required by law or regulation to make any such disclosure of the
     other Party's Confidential Information it will, except where impractical
     for necessary disclosures, for example in the event of a medical emergency,
     give reasonable advance notice to the other Party of such disclosure
     requirement and will use good faith efforts to assist such other Party to
     secure a protective order or confidential treatment of such Confidential
     Information required to be disclosed.

12.5 LIMITATION OF DISCLOSURE: The Parties agree that, except as otherwise may
     be required by applicable laws, regulations, rules or orders, including
     without limitation the rules and regulations promulgated by the United
     States Securities and Exchange Commission, and except as may be authorized
     in Section 12.4, no information concerning this Agreement and the
     transactions contemplated herein shall be made public by either Party
     without the prior written consent of the other.

12.6 PUBLICITY AND SEC FILINGS. The Parties agree that the public announcement
     of the execution of this Agreement shall only be by one or more press
     releases mutually agreed to by the Parties. The failure of a Party to
     return a draft of a press release with its proposed amendments or
     modifications to such press release to the other Party within five (5) days
     of such Party's receipt of such press release shall be deemed as such
     Party's approval of such press release as received by such Party. Each
     Party agrees that it shall cooperate reasonably and in a timely manner with
     the other with respect to all disclosures to the Securities and Exchange
     Commission and any other governmental or regulatory agencies, including
     requests for confidential treatment of Confidential Information of either
     Party included in any such disclosure. It is understood that each Party may
     disclose this Agreement to the extent required by applicable laws or
     regulations, subject to using reasonable efforts to seek confidential
     treatment of sensitive economic, business or technical terms in the
     Agreement as permitted under law.

12.7 DURATION OF CONFIDENTIALITY: All obligations of confidentiality and non-use
     imposed upon the Parties under this Agreement shall expire 10 years after
     the expiration or earlier termination of this Agreement; provided, however,
     that Confidential Information which constitutes the trade secrets of a
     Party shall be kept confidential indefinitely, subject to the limitations
     set forth in Sections 12.4 and 12.5.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       17

<PAGE>

                                   ARTICLE 13

                                   INVENTIONS.

13.1 EXISTING INTELLECTUAL PROPERTY: Except as the Parties may otherwise
     expressly agree in writing, each Party shall continue to own its existing
     patents, trademarks, copyrights, trade secrets and other intellectual
     property, without conferring any interests therein on the other Party.
     Without limiting the generality of the preceding sentence, Altus shall
     retain all right, title and interest arising under the United States Patent
     Act, the United States Trademark Act, the United States Copyright Act and
     all other applicable laws, rules and regulations in and to all Drug
     Product, Bulk Drug Substance, the Process, the Specifications, Labeling and
     trademarks associated therewith, any other Altus technology or know-how
     disclosed to Althea (collectively, "Altus' Intellectual Property"). Except
     as expressly set forth in Section 13.2, Althea shall retain all right,
     title and interest under the same above noted laws to any of its
     manufacturing process technology that existed as of the Effective Date or
     is developed after the Effective Date. Neither Althea nor any third party
     shall acquire any right, title or interest in Altus' Intellectual Property
     by virtue of this Agreement or otherwise, except to the extent expressly
     provided herein.

13.2 MANUFACTURING IMPROVEMENTS. If Althea generates any improvements or other
     inventions, information or know-how based on its work under this Agreement
     that relate to Bulk Drug Substance or Drug Product, including without
     limitation methods relating to the manufacture thereof (collectively, the
     "Manufacturing Improvements"), Althea shall disclose all such Manufacturing
     Improvements to Altus. Altus shall own any such Manufacturing Improvements
     that relate to protein crystallization processes and techniques and/or
     formulations (the "Assigned Improvements"), and Althea shall assign to
     Altus the entire right, title and interest in and to such Assigned
     Improvements. Altus shall grant Althea the limited, non-exclusive,
     non-transferable right for Althea to use any such Assigned Improvements in
     its manufacturing business, but provided that Althea shall not have any
     license to use same to make a product that is competitive with any Altus
     product, product candidate, or technology or is otherwise a crystalline
     protein. Althea shall own the entire right, title and interest in and to
     any other Manufacturing Improvements (that is, those that are not Assigned
     Improvements), and Althea hereby grants and agrees to grant to Altus a
     non-exclusive, worldwide, royalty-free, fully paid, perpetual, irrevocable,
     worldwide license, including the right to sublicense, under any such other
     Manufacturing Improvements solely to make, have made, use, sell, have sold,
     offer for sale and import Bulk Drug Substance, Drug Product and products
     containing Bulk Drug Substance.

13.3 INDIVIDUALLY OWNED INVENTIONS: Except as set forth in Section 13.2, all
     Inventions (as defined herein) which are conceived, reduced to practice, or
     created by a Party in the course of performing its obligations under this
     Agreement shall be solely owned and subject to use and exploitation by the
     inventing Party without a duty to account to the other Party. For purposes
     of this Agreement, "Invention" shall mean information relating to any
     innovation, improvement, development, discovery, computer program, device,
     trade secret, method, know-how, process, technique or the like, whether or
     not written or otherwise fixed in any form or medium, regardless of the
     media on which contained and whether or not patentable or copyrightable.

13.4 JOINTLY OWNED INVENTIONS: Except as set forth in Section 13.2, all
     Inventions which are conceived, reduced to practice, or created jointly by
     the Parties and/or their respective agents (i.e., employees or agents who
     would be or are properly named as co-inventors under the laws of the United
     States on any patent application claiming such inventions) in the course of
     the performance of this Agreement

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       18

<PAGE>

     shall be owned jointly by the Parties. Each Party shall have full rights to
     exploit such Inventions for its own commercial purposes without any
     obligation to the other. The Parties shall share equally in the cost of
     mutually agreed patent filings with respect to all such jointly owned
     Inventions. The decision to file for patent coverage on jointly owned
     Inventions shall be mutually agreed upon, and the Parties shall select a
     mutually acceptable patent counsel to file and prosecute patent
     applications based on such joint Inventions.

13.5 DISCLAIMER: Except as otherwise expressly provided herein, nothing
     contained in this Agreement shall be construed or interpreted, either
     expressly or by implication, estoppel or otherwise, as: (i) a grant,
     transfer or other conveyance by either Party to the other of any right,
     title, license or other interest of any kind in any of its Inventions or
     other intellectual property, (ii) creating an obligation on the part of
     either Party to make any such grant, transfer or other conveyance or (iii)
     requiring either Party to participate with the other Party in any
     cooperative development program or project of any kind or to continue with
     any such program or project.

13.6 RIGHTS IN INVENTIONS: The Party owning any Inventions or Manufacturing
     Improvements shall have the world wide right to control the drafting,
     filing, prosecution and maintenance of patents or other applications or
     registrations for intellectual property rights claiming or covering such
     Inventions or Manufacturing Improvements, including decisions about the
     countries in which to file such patent applications or other applications
     or registrations. All costs and fees associated with the patent and other
     registration activities described in this Section shall be borne by the
     sole owner. Each Party will cooperate with the other Party in the filing
     and prosecution of such patent or other applications and registrations.
     Such cooperation will include, but not be limited to, furnishing supporting
     data and affidavits for the prosecution of patent and other applications
     and registrations and completing and signing forms needed for the
     prosecution, assignment and maintenance of such applications and
     registrations.

13.7 CONFIDENTIALITY OF INVENTIONS: All Inventions or Manufacturing Improvements
     shall be deemed to be the Confidential Information of the Party owning such
     Inventions or Manufacturing Improvements. The protection of each Party's
     Confidential Information is described in Article 12. It shall be the
     responsibility of the Party preparing a patent or other intellectual
     property application or registration to obtain the written permission of
     the other Party to use or disclose the other Party's Confidential
     Information in the application or registration before it is filed and for
     other disclosures made during the prosecution thereof, such permission not
     to be unreasonably withheld or delayed.

                                   ARTICLE 14

                         REPRESENTATIONS AND WARRANTIES.

14.1 MUTUAL REPRESENTATIONS: Each Party hereby represents and warrants to the
     other Party that (a) the person executing this Agreement is authorized to
     execute this Agreement; (b) this Agreement is legal and valid and the
     obligations binding upon such Party are enforceable by their terms; and (c)
     the execution, delivery and performance of this Agreement does not conflict
     with any agreement, instrument or understanding, oral or written, to which
     such Party may be bound, nor violate any law or regulation of any court,
     governmental body or administrative or other agency having jurisdiction
     over it.

14.2 ALTHEA WARRANTY: Althea represents and warrants that Drug Product shall be
     Produced in accordance with cGMP, the Specifications and the Master Batch
     Record, and that the [***]

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       19
<PAGE>

     (excluding adulteration or misbranding resulting solely from the Altus
     Supplied Components incorporated into the applicable Drug Product being
     defective). Althea represents and warrants that it has obtained (or will
     obtain prior to commencing the Production of Drug Product), and will remain
     in compliance with during the term of this Agreement, all permits, licenses
     and other authorizations (the "Permits") which are required under federal,
     state and local laws, rules and regulations applicable to the Production
     only of Drug Product as specified in the Master Batch Record and the
     Project Plan; provided, however, that Althea shall have no obligation to
     obtain Permits relating to the sale, marketing, distribution or use of Bulk
     Drug Substance or Drug Product or with respect to the Labeling of Drug
     Product. Althea makes no representation or warranty with respect to the
     sale, marketing, distribution or use of the Bulk Drug Substance or as to
     printed materials supplied by Altus or its consignee.

14.3 DISCLAIMER OF WARRANTIES: Except for those warranties set forth in Sections
     14.1 and 14.2 of this Agreement, Althea makes no warranties, written, oral,
     express or implied, with respect to Drug Product or the Production of Drug
     Product. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT
     LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
     PARTICULAR PURPOSE AND NONINFRINGEMENT HEREBY ARE DISCLAIMED BY ALTHEA. NO
     WARRANTIES OF ALTHEA MAY BE CHANGED BY ANY REPRESENTATIVES OF ALTHEA. Altus
     accepts Drug Product subject to the terms of this Section 14.3.

14.4 ALTUS WARRANTIES: Altus warrants that (a) it has the right to give Althea
     any information provided by Altus hereunder, and that Althea has the right
     to use such information for the Production of Drug Product, and (b) Altus
     has no knowledge of any (i) patents or other intellectual rights that would
     be infringed by Althea's Production of Drug Product in accordance with the
     terms of this Agreement, or (ii) proprietary rights of third parties which
     would be violated by Althea's performance hereunder. Altus further warrants
     that the Bulk Drug Substance provided to Althea hereunder (1) conforms to
     the Bulk Drug Substance Specifications and (2) is not adulterated or
     misbranded within the meaning of the FD&C Act.

                                   ARTICLE 15

               LIMITATION OF LIABILITY AND WAIVER OF SUBROGATION.

15.1 LIMITATION OF LIABILITY: Altus' sole and exclusive remedy for breach of
     this Agreement is limited to those remedies set forth in Article 8 and at
     Althea's decision, in Althea's sole discretion, to either replace the
     non-conforming Drug Product or reimburse Altus for the Purchase Price for
     the non-conforming Drug Product. Under no circumstances shall Althea be
     liable for loss of use or profits or other collateral, special,
     consequential or other damages, losses, or expenses, including but not
     limited to the cost of cover or the cost of a recall in connection with, or
     by reason of the Production and delivery of Drug Product under this
     Agreement whether such claims are founded in tort or contract. The
     foregoing constitutes the sole and exclusive remedy of Altus and the sole
     and exclusive liability of Althea. All claims by Altus for breach or
     default under this Agreement shall be brought within one (1) year after the
     cause of action accrued or shall be deemed waived.

15.2 WAIVER OF SUBROGATION: All Althea Supplied Components and equipment (other
     than the Equipment) used by Althea in the Production of Drug Product
     (collectively, "Althea Property") shall at all times remain the property of
     Althea and Althea assumes risk of loss for such property until delivery of
     Drug Product to a common carrier as specified under Section 4.9. Althea
     hereby waives

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       20

<PAGE>

     any and all rights of recovery against Altus and its Affiliates, and
     against any of their respective directors, officers, employees, agents or
     representatives, for any loss or damage to Althea Property to the extent
     the loss of damage is covered or could be covered by insurance (whether or
     not such insurance is described in this Agreement). Altus assumes all risk
     of loss for all Altus Supplied Components, all Bulk Drug Substance supplied
     by Altus, and all Drug Product (collectively, "Altus Property"). Altus
     hereby waives any and all rights of recovery against Althea and its
     Affiliates, and against any of their respective directors, officers,
     employees, agents or representatives, for any loss or damage to the Altus
     Property to the extent the loss of damage is covered or could be covered by
     insurance (whether or not such insurance is described in this Agreement).

15.3 WAIVER OF CLAIMS: In connection with providing Production Services, Althea
     represents only that it will use reasonable care in providing such
     information solely as it relates to development studies, formulation,
     primary packaging and manufacturing process development. Althea makes no
     representation or warranty, and Altus expressly waives all claims against
     Althea and its Affiliates, and any of their respective agents or employees,
     arising out of or in connection with any claims relating to the stability,
     efficacy, safety, or toxicity of Drug Product developed, formulated,
     packaged or manufactured in accordance with the Production Services
     provided by Althea.

                                   ARTICLE 16

                                INDEMNIFICATION.

16.1 ALTUS INDEMNIFICATION: Altus shall indemnify, defend and hold harmless
     Althea and its Affiliates, and any of their respective directors, officers,
     employees, subcontractors and agents (collectively the "Indemnified
     Parties") from and against any and all liabilities, obligations, penalties,
     claims, judgments, disbursements of any kind and nature, losses, damages,
     costs and expenses (including, without limitation, reasonable attorney's
     fees) arising out of or in connection with any third party demands,
     actions, or suits resulting from property damage or personal injury
     (including without limitation death) of third parties (collectively
     "Claims") resulting from: (a) Altus' storage, promotion, labeling,
     marketing, distribution, use or sale of Bulk Drug Substance or Drug
     Product, (b) Altus' negligence or willful misconduct, (c) Altus' breach of
     this Agreement, or (d) any claim that the use, sale, Production, marketing
     or distribution of Bulk Drug Substance or Drug Product by Althea or Altus
     violates the patent, trademark, copyright or other proprietary rights of
     any third party, except to the extent any of the foregoing (a) through (d)
     is caused by the negligence or willful misconduct of the Indemnified
     Parties or by the breach by Althea of its obligations under this Agreement.

16.2 ALTHEA INDEMNIFICATION: Althea shall indemnify, defend and hold harmless
     Altus and its Affiliates and any of their respective directors, officers,
     employees, subcontractors and agents from and against any and all Claims
     resulting from any of the Indemnified Parties' (as defined in Section 16.1
     above) negligence or willful misconduct or from Althea's breach of any its
     obligations under this Agreement.

16.3 INDEMNITEE OBLIGATIONS: A Party (the "Indemnitee") which intends to claim
     indemnification under this Article 16 shall promptly notify the other Party
     (the "Indemnitor") in writing of any action, claim or other matter in
     respect of which the Indemnitee or any of its Affiliates, or any of their
     respective directors, officers, employees, subcontractors, or agents,
     intend to claim such indemnification; provided, however, that failure to
     provide such notice within a reasonable period of time shall not relieve
     the Indemnitor of any of its obligations hereunder except to the extent the

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       21
<PAGE>

     Indemnitor is prejudiced by such failure. The Indemnitee shall permit, and
     shall cause its Affiliates, and their respective directors, officers,
     employees, subcontractors and agents to permit, the Indemnitor, at its
     discretion, to settle any such action, claim or other matter, and the
     Indemnitee agrees to the complete control of such defense or settlement by
     the Indemnitor. Notwithstanding the foregoing, the Indemnitor shall not
     enter into any settlement that would adversely affect the Indemnitee's
     rights hereunder, or impose any obligations on the Indemnitee in addition
     to those set forth herein, in order for it to exercise such rights, without
     Indemnitee's prior written consent, which shall not be unreasonably
     withheld or delayed. No such action, claim or other matter shall be settled
     by an Indemnitee without the prior written consent of the Indemnitor, which
     shall not be unreasonably withheld or delayed. The Indemnitee, its
     Affiliates, and their respective directors, officers, employees,
     subcontractors and agents shall fully cooperate with the Indemnitor and its
     legal representatives in the investigation and defense of any action, claim
     or other matter covered by the indemnification obligations of this Article
     16. The Indemnitee shall have the right, but not the obligation, to be
     represented in such defense by counsel of its own selection and at its own
     expense.

16.4 INJUNCTION: In the event that the Production or sale of a Drug Product is
     enjoined due to alleged infringement by either Party of the proprietary
     rights of a third party, such injunction shall permit either Party to
     terminate this Agreement under the terms of Article 6.

                                   ARTICLE 17

                                   INSURANCE.

17.1 ALTUS INSURANCE: Altus shall procure and maintain, during the Term of this
     Agreement and for a period of one (1) year beyond the expiration date of
     Drug Product, Commercial General Liability Insurance and Product Liability
     and Contractual Liability coverage (the "Altus Insurance"). The Altus
     Insurance shall cover amounts not less than [***] combined single limit.
     Altus promptly shall deliver a certificate of Altus Insurance to Althea
     evidencing such coverage. If Altus fails to furnish such certificates or if
     at any time during the Term of this Agreement Althea is notified of the
     cancellation or lapse of the Altus Insurance, and Altus fails to rectify
     the same within 30 calendar days after notice from Althea, in addition to
     all other remedies available to Althea hereunder, Althea, at its option,
     may obtain the Altus Insurance at a reasonable cost and Altus promptly
     shall reimburse Althea for the cost of the same. Any deductible and/or self
     insurance retention shall be the sole responsibility of Altus.

17.2 ALTHEA INSURANCE: Althea shall procure and maintain, during the Term of
     this Agreement and for a period of one (1) year beyond the expiration date
     of Drug Product, Commercial General Liability Insurance and Product
     Liability and Contractual Liability coverage (the "Althea Insurance"). The
     Althea Insurance shall cover amounts not less than [***] combined single
     limit. Althea promptly shall deliver a certificate of Althea Insurance to
     Altus evidencing such coverage. If Althea fails to furnish such
     certificates, or if at any time during the Term of this Agreement Altus is
     notified of the cancellation or lapse of the Althea Insurance, and Althea
     fails to rectify the same within 30 calendar days after notice from Altus,
     in addition to all other remedies available to Altus hereunder, Altus, at
     its option, may obtain the Althea Insurance at reasonable cost, and Althea
     promptly shall reimburse Altus for the cost of the same. Any deductible
     and/or self insurance retention shall be the sole responsibility of Althea.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       22

<PAGE>

                                   ARTICLE 18

                               GENERAL PROVISIONS.

18.1 NOTICES: All notices hereunder shall be delivered by facsimile (confirmed
     by overnight delivery), or by overnight delivery with a reputable overnight
     delivery service, to the following address of the respective Parties:

          If to Altus:    Altus Pharmaceuticals Inc.
                          125 Sidney Street
                          Cambridge, MA  02139
                          Attn:  Chief Financial Officer

                          Telephone: [***]
                          Facsimile: (617) 299-2999

          If to Althea:   Althea Technologies, Inc.
                          11040 Roselle Street
                          San Diego, CA 92121
                          Attn: Chief Financial Officer

                          Telephone: [***]
                          Facsimile: (858) 882-0133

For specific inquiries, the following Althea responsible individuals may be
contacted directly:

     Project Manager             [***]

     Quality Control and
     Quality Assurance Manager   [***]

     Materials Manager           [***]

For specific inquiries, the following Altus responsible individuals may be
contacted directly:

     Project Manager                      [***]

     Director, Quality Assurance          [***]

     Materials Manager                    [***]

     Quality Control Associate Director   [***]

     Notices shall be effective on the day following the date of transmission if
     sent by facsimile, and on the second business day following the date of
     delivery to the overnight delivery service if sent by overnight delivery. A
     Party may change its address listed above, or any listed responsible
     individual, by notice to the other Party given in accordance with this
     section.

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       23

<PAGE>

18.2 ENTIRE AGREEMENT; AMENDMENT: The Parties hereto acknowledge that this
     Agreement sets forth the entire agreement and understanding of the Parties
     and supersedes all prior written or oral agreements or understandings with
     respect to the subject matter hereof, including the letter of intent
     between the Parties dated May 18, 2006, but excluding the Confidentiality
     Agreement between the Parties dated October 4, 2005. No modification of any
     of the terms of this Agreement, or any amendments thereto, shall be deemed
     to be valid unless in writing and signed by an authorized agent or
     representative of both Parties hereto. No course of dealing or usage of
     trade shall be used to modify the terms and conditions herein.

18.3 WAIVER: None of the provisions of this Agreement shall be considered waived
     by any Party hereto unless such waiver is agreed to, in writing, by
     authorized agents of both Parties. The failure of a Party to insist upon
     strict conformance to any of the terms and conditions hereof, or failure or
     delay to exercise any rights provided herein or by law shall not be deemed
     a waiver of any rights of any Party hereto.

18.4 OBLIGATIONS TO THIRD PARTIES: Each Party warrants and represents that this
     Agreement is not inconsistent with any contractual obligations, expressed
     or implied, undertaken with any third party.

18.5 ASSIGNMENT: This Agreement shall be binding upon and inure to the benefit
     of the successors or permitted assigns of each of the Parties and may not
     be assigned or transferred by either Party without the prior written
     consent of the other, which consent will not be unreasonably withheld or
     delayed, except that no consent shall be required in the case of an
     assignment of this Agreement by a Party to its Affiliate or to its
     successor in interest pursuant to a transaction involving the merger,
     consolidation or sale of all or substantially all of the assets of the
     Party and provided that such successor entity assumes in writing all the
     obligations of the assigning Party under this Agreement. No assignment
     shall relieve any Party of responsibility for the performance of its
     obligations hereunder.

18.6 TAXES: Altus shall pay all national, state, municipal or other sales, use
     excise, import, property, value added, or other similar taxes, assessments
     or tariffs assessed upon or levied against the sale of Drug Product to
     Altus pursuant to this Agreement or the sale or distribution of Drug
     Product by Altus (or at Altus' sole expense, defend against the imposition
     of such taxes and expenses). Althea shall notify Altus of any such taxes
     that any governmental authority is seeking to collect from Althea, and
     Altus may assume the defense thereof in Althea's name, if necessary, and
     Althea agrees to fully cooperate in such defense to the extent of the
     capacity of Althea, at Altus' expense. Althea shall pay all national,
     state, municipal or other taxes on the income resulting from the sale by
     Althea of the Drug Product to Altus under this Agreement, including but not
     limited to, gross income, adjusted gross income, supplemental net income,
     gross receipts, excess profit taxes, or other similar taxes.

18.7 INDEPENDENT CONTRACTOR: Althea shall act as an independent contractor for
     Altus in providing the services required hereunder and shall not be
     considered an agent of, or joint venturer with, Altus. Unless otherwise
     provided herein to the contrary, Althea shall furnish all expertise, labor,
     supervision, machining and equipment necessary for performance hereunder
     and shall obtain and maintain all building and other permits and licenses
     required by public authorities.

18.8 GOVERNING LAW: Any action or proceeding seeking to enforce any provision
     of, or based on any right arising out of, this Agreement may be brought by
     either of the Parties, such action shall be

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       24

<PAGE>

     subject to the laws of the State of New York, excluding any conflicts of
     laws provisions that would require application of other laws.

18.9 ATTORNEY'S FEES: The successful Party in any litigation or other dispute
     resolution proceeding to enforce the terms and conditions of this Agreement
     shall be entitled to recover from the other Party reasonable attorney's
     fees and related costs involved in connection with such litigation or
     dispute resolution proceeding.

18.10 SEVERABILITY: In the event that any term or provision of this Agreement
     shall violate any applicable statute, ordinance, or rule of law in any
     jurisdiction in which it is used, or otherwise be unenforceable, such
     provision shall be ineffective to the extent of such violation without
     invalidating any other provision hereof.

18.11 HEADINGS, INTERPRETATION: The headings used in this Agreement are for
     convenience only and are not part of this Agreement. The term "including"
     shall be interpreted to mean "including without limitation" and shall not
     limit the generality of any provision preceding the term.

18.12 COUNTERPARTS; FACSIMILE EXECUTION: This Agreement may be executed in one
     or more counterparts, each of which shall be deemed to be an original copy
     of this Agreement and all of which, when taken together, shall be deemed to
     constitute one and the same agreement. Facsimile execution and delivery of
     this Agreement, is legal, valid and binding for all purposes.

     ****************

     [remainder of page left blank]

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       25

<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have each caused this Drug Product
Production and Clinical Supply Agreement to be executed by their duly-authorized
representatives as of the Effective Date above written.

ALTUS PHARMACEUTICALS INC.              ALTHEA TECHNOLOGIES, INC

By:                                     By:
    ---------------------------------       ------------------------------------
Name:                                   Name:
      -------------------------------         ----------------------------------
Title:                                  Title:
       ------------------------------          ---------------------------------

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       26
<PAGE>

                                   SCHEDULE 1

Final Execution Version

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
 SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       27

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<CAPTION>
                       %Work
 ID     Task Name    Complete   Duration   Start   Finish   [***]   [***]
---   ------------   --------   --------   -----   ------   -----   -----
<S>   <C>            <C>        <C>        <C>     <C>      <C>     <C>
  1    ALTU: [***]     [***]      [***]    [***]    [***]
  2       [***]        [***]      [***]    [***]    [***]
  3       [***]        [***]      [***]    [***]    [***]
  4       [***]        [***]      [***]    [***]    [***]
  5       [***]        [***]      [***]    [***]    [***]
  6       [***]        [***]      [***]    [***]    [***]
  7       [***]        [***]      [***]    [***]    [***]
  8       [***]        [***]      [***]    [***]    [***]
  9       [***]        [***]      [***]    [***]    [***]
 10       [***]        [***]      [***]    [***]    [***]
 11       [***]        [***]      [***]    [***]    [***]
 12       [***]        [***]      [***]    [***]    [***]
 13       [***]        [***]      [***]    [***]    [***]
 14       [***]        [***]      [***]    [***]    [***]
 15       [***]        [***]      [***]    [***]    [***]
 16       [***]        [***]      [***]    [***]    [***]
 17       [***]        [***]      [***]    [***]    [***]
 18       [***]        [***]      [***]    [***]    [***]
 19       [***]        [***]      [***]    [***]    [***]
 20       [***]        [***]      [***]    [***]    [***]
 21       [***]        [***]      [***]    [***]    [***]
 22       [***]        [***]      [***]    [***]    [***]
 23       [***]        [***]      [***]    [***]    [***]
 24       [***]        [***]      [***]    [***]    [***]
 25       [***]        [***]      [***]    [***]    [***]
 26       [***]        [***]      [***]    [***]    [***]
 27       [***]        [***]      [***]    [***]    [***]
 28       [***]        [***]      [***]    [***]    [***]
 29       [***]        [***]      [***]    [***]    [***]
 30       [***]        [***]      [***]    [***]    [***]
 31       [***]        [***]      [***]    [***]    [***]
 32       [***]        [***]      [***]    [***]    [***]
 33       [***]        [***]      [***]    [***]    [***]
 34       [***]        [***]      [***]    [***]    [***]
 35       [***]        [***]      [***]    [***]    [***]
 36       [***]        [***]      [***]    [***]    [***]
 37       [***]        [***]      [***]    [***]    [***]
 38       [***]        [***]      [***]    [***]    [***]
 39       [***]        [***]      [***]    [***]    [***]
 40       [***]        [***]      [***]    [***]    [***]
 41       [***]        [***]      [***]    [***]    [***]
 42       [***]        [***]      [***]    [***]    [***]
 43       [***]        [***]      [***]    [***]    [***]
 44       [***]        [***]      [***]    [***]    [***]
</TABLE>

Project: ALTUS-238 Phase 3 Material   [Gantt Chart Information Redacted]
Date: Tue 8/15/06

Final Execution Version

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
 SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       28

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<CAPTION>
                       %Work
 ID       Task       Complete   Duration   Start   Finish   [***]   [***]
---   ------------   --------   --------   -----   ------   -----   -----
<S>   <C>            <C>        <C>        <C>     <C>      <C>     <C>
 45       [***]        [***]      [***]    [***]    [***]
 46       [***]        [***]      [***]    [***]    [***]
 47       [***]        [***]      [***]    [***]    [***]
 48       [***]        [***]      [***]    [***]    [***]
 49       [***]        [***]      [***]    [***]    [***]
 50       [***]        [***]      [***]    [***]    [***]
 51       [***]        [***]      [***]    [***]    [***]
 52       [***]        [***]      [***]    [***]    [***]
 53       [***]        [***]      [***]    [***]    [***]
 54       [***]        [***]      [***]    [***]    [***]
 55       [***]        [***]      [***]    [***]    [***]
 56       [***]        [***]      [***]    [***]    [***]
 57   ALTUS: [***]     [***]      [***]    [***]    [***]
 58   ALTUS: [***]     [***]      [***]    [***]    [***]
 59       [***]        [***]      [***]    [***]    [***]
 60       [***]        [***]      [***]    [***]    [***]
 61       [***]        [***]      [***]    [***]    [***]
 62       [***]        [***]      [***]    [***]    [***]
 63       [***]        [***]      [***]    [***]    [***]
 64       [***]        [***]      [***]    [***]    [***]
 65       [***]        [***]      [***]    [***]    [***]
 66       [***]        [***]      [***]    [***]    [***]
 67       [***]        [***]      [***]    [***]    [***]
 68       [***]        [***]      [***]    [***]    [***]
 69       [***]        [***]      [***]    [***]    [***]
 70       [***]        [***]      [***]    [***]    [***]
 71       [***]        [***]      [***]    [***]    [***]
 72       [***]        [***]      [***]    [***]    [***]
 73       [***]        [***]      [***]    [***]    [***]
 74       [***]        [***]      [***]    [***]    [***]
 75       [***]        [***]      [***]    [***]    [***]
 76       [***]        [***]      [***]    [***]    [***]
 77       [***]        [***]      [***]    [***]    [***]
 78       [***]        [***]      [***]    [***]    [***]
 79       [***]        [***]      [***]    [***]    [***]
 80       [***]        [***]      [***]    [***]    [***]
 81       [***]        [***]      [***]    [***]    [***]
 82       [***]        [***]      [***]    [***]    [***]
 83       [***]        [***]      [***]    [***]    [***]
 84       [***]        [***]      [***]    [***]    [***]
 85       [***]        [***]      [***]    [***]    [***]
 86       [***]        [***]      [***]    [***]    [***]
 87       [***]        [***]      [***]    [***]    [***]
 88       [***]        [***]      [***]    [***]    [***]
</TABLE>

Project: ALTUS-238 Phase 3 Material   [Gantt Chart Information Redacted]
Date: Tue 8/15/06

Final Execution Version

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
 SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       29

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<CAPTION>
                       %Work
 ID     Task Name    Complete   Duration   Start   Finish   [***]   [***]
---   ------------   --------   --------   -----   ------   -----   -----
<S>   <C>            <C>        <C>        <C>     <C>      <C>     <C>
 89       [***]        [***]      [***]    [***]    [***]
 90       [***]        [***]      [***]    [***]    [***]
 91       [***]        [***]      [***]    [***]    [***]
 92       [***]        [***]      [***]    [***]    [***]
 93       [***]        [***]      [***]    [***]    [***]
 94       [***]        [***]      [***]    [***]    [***]
 95   ALTUS: [***]     [***]      [***]    [***]    [***]
 96       [***]        [***]      [***]    [***]    [***]
 97       [***]        [***]      [***]    [***]    [***]
 98       [***]        [***]      [***]    [***]    [***]
 99       [***]        [***]      [***]    [***]    [***]
100       [***]        [***]      [***]    [***]    [***]
101       [***]        [***]      [***]    [***]    [***]
102       [***]        [***]      [***]    [***]    [***]
103       [***]        [***]      [***]    [***]    [***]
104       [***]        [***]      [***]    [***]    [***]
105       [***]        [***]      [***]    [***]    [***]
106       [***]        [***]      [***]    [***]    [***]
107       [***]        [***]      [***]    [***]    [***]
108       [***]        [***]      [***]    [***]    [***]
109       [***]        [***]      [***]    [***]    [***]
110       [***]        [***]      [***]    [***]    [***]
111       [***]        [***]      [***]    [***]    [***]
112       [***]        [***]      [***]    [***]    [***]
113       [***]        [***]      [***]    [***]    [***]
114       [***]        [***]      [***]    [***]    [***]
115       [***]        [***]      [***]    [***]    [***]
116       [***]        [***]      [***]    [***]    [***]
117       [***]        [***]      [***]    [***]    [***]
118       [***]        [***]      [***]    [***]    [***]
119       [***]        [***]      [***]    [***]    [***]
120       [***]        [***]      [***]    [***]    [***]
121       [***]        [***]      [***]    [***]    [***]
122       [***]        [***]      [***]    [***]    [***]
123       [***]        [***]      [***]    [***]    [***]
124   ALTUS: [***]     [***]      [***]    [***]    [***]
125       [***]        [***]      [***]    [***]    [***]
126       [***]        [***]      [***]    [***]    [***]
127       [***]        [***]      [***]    [***]    [***]
128       [***]        [***]      [***]    [***]    [***]
129       [***]        [***]      [***]    [***]    [***]
130       [***]        [***]      [***]    [***]    [***]
131       [***]        [***]      [***]    [***]    [***]
132       [***]        [***]      [***]    [***]    [***]
</TABLE>

Project: ALTUS-238 Phase 3 Material   [Gantt Chart Information Redacted]
Date: Tue 8/15/06

Final Execution Version

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
 SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       30

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<CAPTION>
                       %Work
 ID     Task Name    Complete   Duration   Start   Finish   [***]   [***]
---   ------------   --------   --------   -----   ------   -----   -----
<S>   <C>            <C>        <C>        <C>     <C>      <C>     <C>
133       [***]        [***]      [***]    [***]    [***]
134       [***]        [***]      [***]    [***]    [***]
135       [***]        [***]      [***]    [***]    [***]
136       [***]        [***]      [***]    [***]    [***]
137       [***]        [***]      [***]    [***]    [***]
138       [***]        [***]      [***]    [***]    [***]
139       [***]        [***]      [***]    [***]    [***]
140       [***]        [***]      [***]    [***]    [***]
141       [***]        [***]      [***]    [***]    [***]
142       [***]        [***]      [***]    [***]    [***]
143       [***]        [***]      [***]    [***]    [***]
144       [***]        [***]      [***]    [***]    [***]
145       [***]        [***]      [***]    [***]    [***]
146       [***]        [***]      [***]    [***]    [***]
147       [***]        [***]      [***]    [***]    [***]
148       [***]        [***]      [***]    [***]    [***]
149       [***]        [***]      [***]    [***]    [***]
150       [***]        [***]      [***]    [***]    [***]
151       [***]        [***]      [***]    [***]    [***]
152       [***]        [***]      [***]    [***]    [***]
153       [***]        [***]      [***]    [***]    [***]
154       [***]        [***]      [***]    [***]    [***]
155       [***]        [***]      [***]    [***]    [***]
156       [***]        [***]      [***]    [***]    [***]
157       [***]        [***]      [***]    [***]    [***]
158       [***]        [***]      [***]    [***]    [***]
159       [***]        [***]      [***]    [***]    [***]
160       [***]        [***]      [***]    [***]    [***]
161   ALTUS: [***]     [***]      [***]    [***]    [***]
162   ALTUS: [***]     [***]      [***]    [***]    [***]
163       [***]        [***]      [***]    [***]    [***]
164       [***]        [***]      [***]    [***]    [***]
165       [***]        [***]      [***]    [***]    [***]
166       [***]        [***]      [***]    [***]    [***]
167       [***]        [***]      [***]    [***]    [***]
168       [***]        [***]      [***]    [***]    [***]
169       [***]        [***]      [***]    [***]    [***]
170       [***]        [***]      [***]    [***]    [***]
171       [***]        [***]      [***]    [***]    [***]
172       [***]        [***]      [***]    [***]    [***]
173       [***]        [***]      [***]    [***]    [***]
174       [***]        [***]      [***]    [***]    [***]
175       [***]        [***]      [***]    [***]    [***]
176   ALTUS: [***]     [***]      [***]    [***]    [***]
</TABLE>

Project: ALTUS-238 Phase 3 Material   [Gantt Chart Information Redacted]
Date: Tue 8/15/06

Final Execution Version

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
 SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       31

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<CAPTION>
                       %Work
 ID     Task Name    Complete   Duration   Start   Finish   [***]   [***]
---   ------------   --------   --------   -----   ------   -----   -----
<S>   <C>            <C>        <C>        <C>     <C>      <C>     <C>
177       [***]        [***]      [***]    [***]    [***]
178       [***]        [***]      [***]    [***]    [***]
179       [***]        [***]      [***]    [***]    [***]
180       [***]        [***]      [***]    [***]    [***]
181       [***]        [***]      [***]    [***]    [***]
182       [***]        [***]      [***]    [***]    [***]
183       [***]        [***]      [***]    [***]    [***]
184       [***]        [***]      [***]    [***]    [***]
185       [***]        [***]      [***]    [***]    [***]
186       [***]        [***]      [***]    [***]    [***]
187       [***]        [***]      [***]    [***]    [***]
188       [***]        [***]      [***]    [***]    [***]
189       [***]        [***]      [***]    [***]    [***]
190   ALTUS: [***]     [***]      [***]    [***]    [***]
191   ALTUS: [***]     [***]      [***]    [***]    [***]
192       [***]        [***]      [***]    [***]    [***]
193       [***]        [***]      [***]    [***]    [***]
194       [***]        [***]      [***]    [***]    [***]
195       [***]        [***]      [***]    [***]    [***]
196       [***]        [***]      [***]    [***]    [***]
197       [***]        [***]      [***]    [***]    [***]
198       [***]        [***]      [***]    [***]    [***]
199       [***]        [***]      [***]    [***]    [***]
200       [***]        [***]      [***]    [***]    [***]
201       [***]        [***]      [***]    [***]    [***]
202       [***]        [***]      [***]    [***]    [***]
203   ALTUS: [***]     [***]      [***]    [***]    [***]
204       [***]        [***]      [***]    [***]    [***]
205       [***]        [***]      [***]    [***]    [***]
206   ALTUS: [***]     [***]      [***]    [***]    [***]
207       [***]        [***]      [***]    [***]    [***]
208       [***]        [***]      [***]    [***]    [***]
209       [***]        [***]      [***]    [***]    [***]
210       [***]        [***]      [***]    [***]    [***]
211   ALTUS: [***]     [***]      [***]    [***]    [***]
212       [***]        [***]      [***]    [***]    [***]
213       [***]        [***]      [***]    [***]    [***]
214       [***]        [***]      [***]    [***]    [***]
215       [***]        [***]      [***]    [***]    [***]
216   ALTUS: [***]     [***]      [***]    [***]    [***]
217       [***]        [***]      [***]    [***]    [***]
218       [***]        [***]      [***]    [***]    [***]
219       [***]        [***]      [***]    [***]    [***]
220       [***]        [***]      [***]    [***]    [***]
</TABLE>

Project: ALTUS-238 Phase 3 Material   [Gantt Chart Information Redacted]
Date: Tue 8/15/06

Final Execution Version

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
 SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       32

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<CAPTION>
                       %Work
 ID     Task Name    Complete   Duration   Start   Finish   [***]   [***]
---   ------------   --------   --------   -----   ------   -----   -----
<S>   <C>            <C>        <C>        <C>     <C>      <C>     <C>
221       [***]        [***]      [***]    [***]    [***]
222       [***]        [***]      [***]    [***]    [***]
223       [***]        [***]      [***]    [***]    [***]
224       [***]        [***]      [***]    [***]    [***]
225       [***]        [***]      [***]    [***]    [***]
226       [***]        [***]      [***]    [***]    [***]
227       [***]        [***]      [***]    [***]    [***]
228       [***]        [***]      [***]    [***]    [***]
229       [***]        [***]      [***]    [***]    [***]
230       [***]        [***]      [***]    [***]    [***]
231       [***]        [***]      [***]    [***]    [***]
232       [***]        [***]      [***]    [***]    [***]
233       [***]        [***]      [***]    [***]    [***]
234       [***]        [***]      [***]    [***]    [***]
235       [***]        [***]      [***]    [***]    [***]
236       [***]        [***]      [***]    [***]    [***]
237       [***]        [***]      [***]    [***]    [***]
238       [***]        [***]      [***]    [***]    [***]
239   ALTUS: [***]     [***]      [***]    [***]    [***]
240       [***]        [***]      [***]    [***]    [***]
241       [***]        [***]      [***]    [***]    [***]
242       [***]        [***]      [***]    [***]    [***]
243       [***]        [***]      [***]    [***]    [***]
244       [***]        [***]      [***]    [***]    [***]
245       [***]        [***]      [***]    [***]    [***]
246       [***]        [***]      [***]    [***]    [***]
247       [***]        [***]      [***]    [***]    [***]
248       [***]        [***]      [***]    [***]    [***]
249       [***]        [***]      [***]    [***]    [***]
250       [***]        [***]      [***]    [***]    [***]
251       [***]        [***]      [***]    [***]    [***]
252       [***]        [***]      [***]    [***]    [***]
253       [***]        [***]      [***]    [***]    [***]
254       [***]        [***]      [***]    [***]    [***]
255       [***]        [***]      [***]    [***]    [***]
256       [***]        [***]      [***]    [***]    [***]
257       [***]        [***]      [***]    [***]    [***]
258       [***]        [***]      [***]    [***]    [***]
259       [***]        [***]      [***]    [***]    [***]
260       [***]        [***]      [***]    [***]    [***]
261       [***]        [***]      [***]    [***]    [***]
262       [***]        [***]      [***]    [***]    [***]
263       [***]        [***]      [***]    [***]    [***]
264       [***]        [***]      [***]    [***]    [***]
</TABLE>

Project: ALTUS-238 Phase 3 Material   [Gantt Chart Information Redacted]
Date: Tue 8/15/06

Final Execution Version

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
 SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       33

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<CAPTION>
                       %Work
 ID     Task Name    Complete   Duration   Start   Finish   [***]   [***]
---   ------------   --------   --------   -----   ------   -----   -----
<S>   <C>            <C>        <C>        <C>     <C>      <C>     <C>
265       [***]        [***]      [***]    [***]    [***]
266       [***]        [***]      [***]    [***]    [***]
267       [***]        [***]      [***]    [***]    [***]
268       [***]        [***]      [***]    [***]    [***]
269       [***]        [***]      [***]    [***]    [***]
270       [***]        [***]      [***]    [***]    [***]
271       [***]        [***]      [***]    [***]    [***]
272       [***]        [***]      [***]    [***]    [***]
273       [***]        [***]      [***]    [***]    [***]
274       [***]        [***]      [***]    [***]    [***]
275       [***]        [***]      [***]    [***]    [***]
276       [***]        [***]      [***]    [***]    [***]
277       [***]        [***]      [***]    [***]    [***]
278       [***]        [***]      [***]    [***]    [***]
279       [***]        [***]      [***]    [***]    [***]
280       [***]        [***]      [***]    [***]    [***]
281       [***]        [***]      [***]    [***]    [***]
282       [***]        [***]      [***]    [***]    [***]
283       [***]        [***]      [***]    [***]    [***]
284       [***]        [***]      [***]    [***]    [***]
285       [***]        [***]      [***]    [***]    [***]
286       [***]        [***]      [***]    [***]    [***]
287       [***]        [***]      [***]    [***]    [***]
288       [***]        [***]      [***]    [***]    [***]
289       [***]        [***]      [***]    [***]    [***]
290       [***]        [***]      [***]    [***]    [***]
291       [***]        [***]      [***]    [***]    [***]
292       [***]        [***]      [***]    [***]    [***]
293       [***]        [***]      [***]    [***]    [***]
294       [***]        [***]      [***]    [***]    [***]
295       [***]        [***]      [***]    [***]    [***]
296       [***]        [***]      [***]    [***]    [***]
297       [***]        [***]      [***]    [***]    [***]
298       [***]        [***]      [***]    [***]    [***]
299       [***]        [***]      [***]    [***]    [***]
300       [***]        [***]      [***]    [***]    [***]
301       [***]        [***]      [***]    [***]    [***]
302       [***]        [***]      [***]    [***]    [***]
303       [***]        [***]      [***]    [***]    [***]
304       [***]        [***]      [***]    [***]    [***]
</TABLE>

Project: ALTUS-238 Phase 3 Material   [Gantt Chart Information Redacted]
Date: Tue 8/15/06

Final Execution Version

 PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
 SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       34
<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       35

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]  [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       36

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       37

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       38

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       39

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       40

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       41

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       42

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       43

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       44

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       45
<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       46

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       47

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       48

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       49

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       50

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       51

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       52

<PAGE>

                           ALTUS-238 Phase 3 Material

<TABLE>
<S>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
[***]                                           [***]                                   [***]
[***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]   [***]
</TABLE>

                        Gantt Chart Information Redacted

Project: ALTUS-238 Phase 3   [Gantt Chart Information Redacted]
Material
Date: Tue 8/15/06

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       53

<PAGE>

                                   SCHEDULE 2

                                    EQUIPMENT

The Equipment owned by Altus to be used in this project includes:

     1.   [***]

     2.   [***]

     3.   [***]

     4.   [***]

     5.   [***]

     6.   API Thawing Cabinet (to be detailed later)

     7.   Vessel Temperature Controller ([***] chiller/heater) (to be detailed
          later)

     8.   Product Transfer Tank Filling Support Stand (to be detailed later)

     9.   Product Transfer Tank Autoclave Support Stand to be detailed later

     10.  Product Transfer Tank Transfer Stand (to be detailed later)

     11.  Spare Parts (to be detailed later)

     12.  Storage Crates (to be used WHENEVER equipment is stored -- to be
          detailed later)

     13.  Filter Integrity Tester (to be detailed later)

     14.  [***] Labeling System MOP3 (to be detailed later)

Other items and details may be included later as addendum to Schedule 2

Final Execution Version

  PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
  SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

                                       54

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]